Acetal type releasable polyoxyethylene derivative, preparation method thereof and acetal type releasable polyoxyethylene combination

An acetal-type releasable polyoxyethylene derivative allows for the gradual release of biological functional molecules under physiological conditions, addressing the limitations of existing technologies by maintaining pharmacological efficacy.

CN119072516APending Publication Date: 2024-12-03NOF CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380035693.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-22
Filing Date
2023-04-19
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing prodrug conversion technologies for biological functional molecules do not effectively release these molecules at an appropriate rate under physiological conditions (pH 7.4) to maintain pharmacological effects.

Method used

Development of an acetal-type releasable polyoxyethylene derivative that hydrolyzes under physiological conditions, allowing gradual release of biological functional molecules by benzyl detachment.

Benefits of technology

The derivative extends the half-life of biological functional molecules in the bloodstream and ensures gradual release under neutral conditions, enhancing pharmacological effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072516A_ABST
    Figure CN119072516A_ABST
Patent Text Reader

Abstract

The present invention provides an acetal-type releasable polyoxyethylene derivative which has a specific structure and breaks under physiological conditions, a method for preparing the same, and an acetal-type releasable polyoxyethylene conjugate. The acetal-type releasable polyoxyethylene derivative is capable of releasing a biological functional molecule at an appropriate rate under physiological conditions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an acetal-type releasable polyoxyethylene derivative and a preparation method thereof, and an acetal-type releasable polyoxyethylene conjugate as a conjugate conjugated with a biological functional molecule. Background Art

[0002] When using biological function molecules, when medicines such as hormones, cytokines and enzymes are applied to common living bodies, they can be rapidly discharged from living bodies by glomerular filtration in the kidney and the uptake of macrophages in the liver or spleen. Therefore, the half-life of the drug in the blood is very short, and it is often difficult to obtain enough pharmacological actions. In order to address this problem, attempts have been made to chemically modify biological function molecules with water-soluble polymers such as polyoxyethylene (PEG). As a result, the half-life of biological function molecules in the blood can be extended by increasing molecular weight and forming a hydration layer. As is well known, these modifications can produce effects such as reducing the toxicity and antigenicity of biological function molecules, improving agglutination properties.

[0003] However, it is well known that chemical modification of biofunctional molecules with water-soluble polymers such as PEG may produce adverse effects, such as reduced interaction with target endogenous molecules or receptors due to the formation of a hydration layer or spatial shielding effect of active sites by water-soluble polymers, resulting in reduced intrinsic pharmacological effects of biofunctional molecules or changes in in vivo or cellular dynamics.

[0004] As a method for solving the above problems, a method is used in which a biofunctional molecule is chemically modified with a water-soluble polymer via a temporary bond, and the temporary bond is cleaved in vivo to release the biofunctional molecule that has not been chemically modified, namely, a prodrug conversion method.

[0005] In recent years, for biofunctional molecules modified with water-soluble polymers, it is known that the technology described in patent documents 1 and 2 can prevent the reduction of the intrinsic pharmacological effects of biofunctional molecules and the changes in dynamics in living bodies or cells by using prodrug conversion methods. Patent documents 1 and 2 report the PEGylation hGH and PEGylation IL-2 obtained by modifying human growth hormone (hGH) and interleukin 2 (IL-2) as biofunctional molecules via a linker, which is non-enzyme dependent and decomposes at an appropriate rate under physiological conditions, i.e., neutral conditions, PEGylation hGH and PEGylation IL-2 can extend its half-life in the blood, and can improve the pharmacological effect reduction caused by PEGization by releasing biofunctional molecules when the linker decomposes. Therefore, prodrug conversion technology is very important, which can extend the half-life of biofunctional molecules in the blood, and release biofunctional molecules at an appropriate rate under physiological conditions in a non-enzyme dependent manner to exert pharmacological effects.

[0006] Patent Document 3 reports a compound that cleaves temporary bonds in a biofunctional molecule chemically modified with PEG in an enzyme-independent manner, thereby releasing the biofunctional molecule that has not been chemically modified.

[0007] Specifically, it was reported that the hydrolysis of linkers with acetal structures under acidic conditions triggers the cleavage of the carbamate bond as a temporary bond through 1,4- or 1,6-benzyl detachment, thereby releasing the biofunctional molecule without chemical modification.

[0008] Prior art documents

[0009] Patent Literature

[0010] Patent Document 1: JP2018-150311A

[0011] Patent Document 2: JP2022-000043A

[0012] Patent Document 3: JP2018-172648A Summary of the invention

[0013] Problems to be solved by the present invention

[0014] In the examples of Patent Document 3, a specific structure capable of releasing biofunctional molecules in an enzyme-independent manner under acidic conditions is exemplified. However, there is currently no description of a prodrug conversion technology capable of releasing biofunctional molecules at an appropriate rate and exerting a pharmacological effect in an enzyme-independent manner under physiological conditions, i.e., neutral conditions of about pH 7.4.

[0015] An object of the present invention is to provide a polyoxyethylene derivative having an acetal structure, a stable preparation method thereof, and an acetal-type releasable polyoxyethylene conjugate, wherein the polyoxyethylene derivative having an acetal structure is characterized in that it converts a biological functional molecule into a prodrug and gradually releases the biological functional molecule under physiological conditions.

[0016] Technical solutions to the problem

[0017] As a result of intensive research, the present inventors have discovered a polyoxyethylene derivative having an acetal structure, a stable preparation method thereof and an acetal-type releasable polyoxyethylene conjugate, wherein the polyoxyethylene derivative having an acetal structure is characterized in that it converts a biological functional molecule into a prodrug and gradually hydrolyzes the acetal under physiological conditions to induce the detachment of the benzyl group.

[0018] That is, the present invention relates to the following [1] to [6].

[0019] [1] An acetal-type releasable polyoxyethylene derivative, the acetal-type releasable polyoxyethylene derivative being represented by the following formula (1), formula (2), formula (3) or formula (4), and being cleaved under physiological conditions,

[0020] [Chemical formula 1]

[0021]

[0022] [Chemical formula 2]

[0023]

[0024] [Chemical formula 3]

[0025]

[0026] [Chemical formula 4]

[0027]

[0028] In formula (1), formula (2), formula (3) and formula (4),

[0029] B 1 represents a hydrogen atom or -C(R 1 )(R 2 )OC(O)E 1 ,

[0030] E 1 represents the leaving group,

[0031] P 1 represents a polyoxyethylene derivative having a dehydroxylated group,

[0032] w represents an integer from 1 to 8,

[0033] R 1 , R 2 , R 3 , R 4 , R 5 and R 11 each independently represents a hydrocarbon group having 1 to 10 carbon atoms or a hydrogen atom,

[0034] R 6 , R 7 , R 8 , R 9 and R 10 each independently represents an electron-withdrawing substituent, an electron-donating substituent or a hydrogen atom, and

[0035] m represents 0 or 1.

[0036] [2] The acetal-type releasable polyoxyethylene derivative according to [1], wherein m represents 0, R 1 and R 2 represents a hydrogen atom, and R 3 , R 4 , R 5 and R 11 Each independently represents a hydrogen atom or a methyl group.

[0037] [3] A method for producing the acetal-type releasable polyoxyethylene derivative according to [1] or [2], the method comprising:

[0038] A coupling step of coupling the polyoxyethylene derivative with the hydroxybenzaldehyde derivative to obtain a coupling product represented by the following formula (5) or formula (6);

[0039] Acetalization step, after the coupling step, reacting the coupling product represented by formula (5) or (6) with a hydroxymethyl group at the 2-position and a substituent (-CH=CB) at the 4-position or the 6-position 1 ) m C(R 1 )(R 2 )-OH(B 1 ,m,R 1 and R 2 as described above) under acidic conditions to obtain an acetal structure; and

[0040] A leaving group structure introduction step, after the acetalization step, a leaving group structure (-OC(O)E 1 ) is introduced into the 4-position or 6-position terminal of the substituent.

[0041] [Chemical formula 5]

[0042]

[0043] [Chemical formula 6]

[0044]

[0045] In formula (5) or (6), P 1 ,w,R 6 , R 7 , R 8 , R 9 and R 10 As defined above.

[0046] [4] According to the method for producing an acetal-type releasable polyoxyethylene derivative described in [3], the method further includes: a deprotection step between the acetalization step and the leaving group structure introduction step, deprotecting the amino group protected by the protecting group in the coupling product represented by formula (5) and formula (6); and a step of introducing a group capable of reacting with a biological functional molecule into the deprotected amino group after the deprotection step.

[0047] [5] An acetal-type releasable polyoxyethylene conjugate, the acetal-type releasable polyoxyethylene conjugate being represented by the following formula (7), formula (8), formula (9) or formula (10), and being broken under physiological conditions,

[0048] [Chemical formula 7]

[0049]

[0050] [Chemical formula 8]

[0051]

[0052] [Chemical formula 9]

[0053]

[0054] [Chemical formula 10]

[0055]

[0056] In formula (7), formula (8), formula (9) and formula (10),

[0057] B 2 represents a hydrogen atom or -C(R 1 )(R 2 )OC(O)NHD 1 ,

[0058] D 1 represents a residue obtained by removing an amino group constituting a carbamate bond from an amino group contained in a biofunctional molecule,

[0059] P 2 It means a polyoxyethylene derivative having a dehydroxylation group, or a combination of a biofunctional molecule and a polyoxyethylene ether derivative having a dehydroxylation group,

[0060] w represents an integer from 1 to 8,

[0061] R 1 , R 2 , R 3 , R 4 , R 5 and R 11each independently represents a hydrocarbon group having 1 to 10 carbon atoms or a hydrogen atom,

[0062] R 6 , R 7 , R 8 , R 9 and R 10 each independently represents an electron-withdrawing substituent, an electron-donating substituent or a hydrogen atom, and

[0063] m represents 0 or 1.

[0064] [6] A method for producing the acetal-type releasable polyoxyethylene conjugate according to [5], the method comprising:

[0065] a coupling step, reacting the acetal-type releasable polyoxyethylene derivative of [1] or [2] with a biofunctional molecule in a neutral or alkaline buffer, wherein the buffer may contain a water-soluble organic solvent; and

[0066] The purification step, after the coupling step, is carried out under neutral or alkaline conditions.

[0067] Effects of the Invention

[0068] The acetal-type releasable polyoxyethylene derivative of the present invention can improve the pharmacological effects of physiological functional molecules modified with polyoxyethylene derivatives by converting the biological functional molecules into prodrugs and gradually hydrolyzing the acetal under physiological conditions to induce the benzyl group to separate and gradually release the biological functional molecules.

[0069] Note that although the examples of Patent Document 3 illustrate specific structures capable of releasing biofunctional molecules under acidic conditions in an enzyme-independent manner, there is no description of specific structures capable of releasing biofunctional molecules under physiological conditions, i.e., neutral conditions of about pH 7.4, by benzyl detachment induced by acetal hydrolysis.

[0070] Here, the acetal structure in the compound of Patent Document 3 is generally used as a protecting group for a diol or a carbonyl group, and it is known that its deprotection is carried out under acidic conditions, and it is stable under neutral or alkaline conditions. Therefore, in the compound of Patent Document 3, there is no suggestion of producing a compound that releases a physiologically functional molecule by hydrolysis at an appropriate rate under physiological conditions, i.e., under neutral conditions.

[0071] The production method in Patent Document 3 includes a step of coupling a phenolic hydroxyl group of a low molecular weight compound having an acetal structure with a hydroxyl group of PEG under alkaline conditions, but it has been found that when the acetal-type releasable polyethylene oxide derivative of the present invention is produced by a coupling step similar to that of Patent Document 3, the acetal structure in the low molecular weight compound becomes unstable, making it difficult to obtain the acetal-type releasable polyethylene oxide derivative of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0072] Figure 1 The results of decomposition tests performed at 40° C. in a deuterium oxide buffer having a pD of 7.4 using the compounds represented by formulae (50), (51), (52), and (53) are shown.

[0073] Figure 2 The results of HPLC analysis of the purified PEGylated RNase described in Example 13 are shown.

[0074] Figure 3 The results of decomposition tests performed at 40°C in a deuterium oxide buffer having a pD of 7.4 using the compounds represented by formulae (75), (76), (77) and (78) are shown.

[0075] Figure 4 The nucleotide sequence of the aptamer having TNFα inhibitory activity is shown.

[0076] Figure 5 (A) shows the HPLC analysis results of the purified PEG(20k)-OCO-NH-C6-(Apt-TNFα) described in Comparative Example 3, and (B) shows the HPLC analysis results of the purified 2MPEG(20k)-OCO-NH-C6-(Apt-TNFα) described in Example 25.

[0077] Figure 6 The results of evaluating the TNFα inhibitory activity using PEG(20k)-OCO-NH-C6-(Apt-TNFα), 2MPEG(20k)-OCO-NH-C6-(Apt-TNFα), and NH2-C6-(Apt-TNFα) obtained by modifying the 5' end of the aptamer of sequence number 1 with a C6 amino linker are shown.

[0078] Figure 7 (A) shows the results of HPLC analysis of the purified PEG(20k)-OCO-NH-insulin described in Comparative Example 4. And (B) shows the results of HPLC analysis of the purified 2MPEG(20k)-OCO-NH-insulin described in Example 26.

[0079] Figure 8 (A) shows the results of stability evaluation of PEG(20k)-OCO-NH-insulin in buffers of various pH values, and (B) shows the results of stability evaluation of 2MPEG(20k)-OCO-NH-insulin in buffers of various pH values. DETAILED DESCRIPTION

[0080] The present invention will be described in detail below.

[0081] The present invention is characterized in that, under physiological conditions, the acetal undergoes hydrolysis, then the benzyl group is detached, and the biofunctional molecule is gradually released. In this specification, "physiological conditions" refers to pH 6.0 to 8.0.

[0082] In addition, the release rate of the biofunctional molecule under physiological conditions can be evaluated as the half-life of the acetal in a buffer solution at pH 7.4. The half-life of the acetal in a buffer solution at pH 7.4 is preferably 0.5 to 35 days. Here, "half-life" refers to the time required for the acetal to be hydrolyzed to convert its 1 / 2 equivalent into an aldehyde.

[0083] The compounds in which a polyoxyethylene derivative is introduced into the 3-position of a phenyl group bonded to an acetal via an ether bond as exemplified in the examples of Patent Document 3 cannot achieve the above-mentioned acetal half-life under physiological conditions. In contrast, the present inventors have found that compounds in which a polyoxyethylene derivative is introduced into the 2-position or 4-position of a phenyl group bonded to an acetal via an ether bond can achieve the above-mentioned acetal half-life when used under physiological conditions.

[0084] That is, the present invention is an acetal-type releasable polyoxyethylene derivative which is represented by the following formula (1), (2), (3) or (4) and cleaves under physiological conditions.

[0085] [Chemical formula 11]

[0086]

[0087] [Chemical formula 12]

[0088]

[0089] [Chemical formula 13]

[0090]

[0091] [Chemical formula 14]

[0092]

[0093] In formula (1), formula (2), formula (3) and formula (4),

[0094] B 1 represents a hydrogen atom or -C(R 1 )(R 2 )OC(O)E 1 ,

[0095] E 1 represents the leaving group,

[0096] P 1represents a polyoxyethylene derivative having a dehydroxylated group,

[0097] w represents an integer from 1 to 8,

[0098] R 1 , R 2 , R 3 , R 4 , R 5 and R 11 each independently represents a hydrocarbon group having 1 to 10 carbon atoms or a hydrogen atom,

[0099] R 6 , R 7 , R 8 , R 9 and R 10 each independently represents an electron-withdrawing substituent, an electron-donating substituent or a hydrogen atom, and

[0100] m represents 0 or 1.

[0101] In formulas (1) to (4), R will be described in detail later. 1 , R 2 and E 1 , and B 1 represents a hydrogen atom or -C(R 1 )(R 2 )OC(O)E 1 , and preferably represents a hydrogen atom.

[0102] In equations (1) to (4), E 1 represents a leaving group, and preferred examples of the leaving group include a succinimidyloxy group, a phthalimidyloxy group, a 4-nitrophenoxy group, a 1-imidazolyloxy group, a pentafluorophenoxy group, a benzotriazol-1-yloxy group, and a 7-azabenzotriazol-1-yloxy group, more preferably a succinimidyloxy group, a 4-nitrophenoxy group, a 1-imidazolyloxy group, a pentafluorophenoxy group, and still more preferably a succinimidyloxy group and a 4-nitrophenoxy group.

[0103] In equations (1) to (4), P 1 dehydroxylated polyoxyethylene derivatives, specifically dehydroxylated polyoxyethylene derivatives (P 1 The polyoxyethylene includes both polyoxyethylene having a molecular weight distribution obtained by polymerization of ethylene oxide and monodisperse polyoxyethylene obtained by coupling oligooxyethylenes having a single molecular weight.

[0104] Depending on the number of W, P 1 Preferred examples include the following residues.

[0105] When w=1, the residue is represented by the following formula (p1) or (p2).

[0106] [Chemical formula 15]

[0107]

[0108] (X 1 represents a hydrocarbon group having 1 to 24 carbon atoms, an amino group protected by a protecting group, or a group capable of reacting with a biological functional molecule,

[0109] Z 1 represents a divalent spacer or a single bond,

[0110] n and l each independently represent 3 to 2000, and

[0111] s represents 0 or 1, t represents 2 or 3, and v represents 0 or 2. ) When w=2, the residue is represented by the following formula (p3) or (p4).

[0112] [Chemical formula 16]

[0113]

[0114] (X 1 , Z 1 , n, l, s and t are as defined above. )When w=3, the residue is represented by the following formula (p5).

[0115] [Chemical formula 17]

[0116]

[0117] (n is as defined above.)

[0118] When w=4, the residue is represented by the following formula (p6), (p7) or (p8).

[0119] [Chemical formula 18]

[0120]

[0121] (X 1 , Z 1 , n, l, s and t are as defined above. )When w=5, the residue is represented by the following formula (p9).

[0122] [Chemical formula 19]

[0123]

[0124] (n is as defined above.)

[0125] When w=6, the residue is represented by the following formula (p10).

[0126] [Chemical formula 20]

[0127]

[0128] (n is as defined above.)

[0129] When w=8, the residue is represented by the following formula (p11), (p12) or (p13).

[0130] [Chemical formula 21]

[0131]

[0132] The symbol "*" indicates the bonding point to the oxygen atom.

[0133] In formulae (p1) to (p13), n and l both represent the number of added moles of oxyethylene groups represented by -(OCH2CH2)-, and each independently represents 3 to 2000, preferably 20 to 1500, more preferably 40 to 1000, and still more preferably 60 to 500, and can be obtained by subtracting the number average molecular weight derived from -(OCH2CH2)- from the number average molecular weight of the polyoxyethylene derivative determined by size exclusion chromatography, mass spectrometry, or the like. n - is the molecular weight of the molecule other than the polyoxyethylene chain represented by, and then the result is divided by the molecular weight derived from the oxyethylene group, 44, to calculate.

[0134] In formula (p1), (p2), (p4) and (p8), Z 1 Indicates the connection between polyoxyethylene and X 1 The divalent spacer or single bond is not particularly limited as long as it is more stable than the acetal structure, and is preferably an ether bond, an ester bond, a carbonate bond, a carbamate bond, an amide bond, a secondary amino group or an alkylene group containing the above groups. The alkylene group has 1 to 24 carbon atoms, and examples thereof include the spacers (z1) to (z8) described in group (I).

[0135] Group(I)

[0136] [Chemical formula 22]

[0137]

[0138] In the formula, q1 and q2 each independently represent an integer of 1 to 12. For example, when it is desired to bind the terminal active carbonate group in a hydrophobic environment such as the inside of a protein, it is preferred that q1 and q2 are larger, whereas when it is desired to bind in a hydrophilic environment, it is preferred that q1 and q2 are smaller. 1represents an ether bond, an ester bond, a carbonate bond, a urethane bond, an amide bond, a secondary amino group or an alkylene group containing the above groups, and when a plurality of the same structural units are bonded, the number of the structural units is 2 or less.

[0139] In formula (p1), (p2), (p4) and (p8), X 1 It represents a hydrocarbon group having 1 to 24 carbon atoms, an amino group protected by a protecting group, or a group capable of reacting with a biological functional molecule.

[0140] Specific examples of the hydrocarbon group include methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, isopentyl, hexyl, heptyl, 2-ethylhexyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, heneicosyl, docosyl, tricosyl, tetracosyl, phenyl, benzyl, cresol, butylphenyl, dodecylphenyl and trityl, preferably a hydrocarbon group having 1 to 10 carbon atoms, more preferably a methyl group or an ethyl group, and still more preferably a methyl group.

[0141] Here, blocking group is the composition that prevents or suppresses the reaction of specific chemical reactive functional group in molecule under specific reaction conditions. Blocking group changes according to the type of chemical reactive functional group to be protected, the conditions of use and the presence of other functional groups or blocking groups in the molecule. The specific example of blocking group can be found in many general textbooks, for example, "Wuts, PGM; Greene, TW Protective Groups in Organic Synthesis, 4th Edition; Wiley-Interscience: New York, 2007". In the present invention, the example of amino protected by blocking group includes amino or azido protected by acyl blocking group or carbamate blocking group, and the specific example of acyl blocking group or carbamate blocking group includes trifluoroacetyl, 9-fluorenylmethyloxycarbonyl and 2-(trimethylsilyl)ethoxycarbonyl etc.

[0142] Examples of the group capable of reacting with the biofunctional molecule include formyl, epoxy, maleimide, vinylsulfone, acryloyl, sulfonyloxy, carboxyl, dithiopyridyl, α-haloacetyl, alkynyl, allyl, vinyl, and azido groups.

[0143] More specifically, examples of functional groups that can react with the amino group of the biological function molecule to form a covalent bond include formyl, epoxy, maleimide, vinyl sulfone, acryl, sulfonyloxy and carboxyl. Examples of functional groups that can react with the sulfhydryl group of the biological function molecule to form a covalent bond include formyl, epoxy, maleimide, vinyl sulfone, acryl, sulfonyloxy, carboxyl, dithiopyridyl, α-haloacetyl, alkynyl, allyl and vinyl. The functional group that can react with the alkynyl group of the biological function molecule to form a covalent bond can be an azido. The functional group that can react with the azido group of the biological function molecule to form a covalent bond can be an alkynyl or a functional group with a triple bond.

[0144] In a preferred embodiment of this aspect, the group capable of reacting with the biofunctional molecule is a group represented by group (II), group (III), group (IV) or group (V). 1 The junction point.

[0145] Group (II): functional groups that can react with the amino groups of biofunctional molecules to form covalent bonds

[0146] The following (a), (b), (e) and (f)

[0147] Group (III): functional groups that can react with the thiol groups of biological functional molecules to form covalent bonds

[0148] The following (a), (b), (c), (d), (e), (f) and (h)

[0149] Group (IV): functional groups that can react with the alkyne groups of biological functional molecules to form covalent bonds

[0150] The following (c), (d) and (g)

[0151] Group (V): Functional groups that can react with the azide group of biological functional molecules to form covalent bonds. The following (i) and (j)

[0152] [Chemical formula 23]

[0153]

[0154] In the formula, Y 1 and Y 3 Each independently represents a hydrogen atom or a hydrocarbon group having 1 to 5 carbon atoms, and specific examples of the hydrocarbon group include methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, and the like. 2 represents a halogen atom selected from a chlorine atom, a bromine atom and an iodine atom.

[0155] In formulae (p2), (p4) and (p8), s represents 0 or 1, t represents 2 or 3, and v represents 0 or 2, and preferred embodiments are residues represented by the following formulae (p14) to (p19).

[0156] [Chemical formula 24]

[0157]

[0158] In formulas (p14) to (p19), X 1 , Z 1 , n and l are as defined above.

[0159] In formulas (1) to (4), R 1 , R 2 , R 3 , R 4 , R 5 and R 11 Each independently represents a hydrocarbon group having 1 to 10 carbon atoms or a hydrogen atom, and specific examples of the hydrocarbon group include methyl, ethyl, propyl, isopropyl, tert-butyl, phenyl and benzyl, more preferably a hydrogen atom or a methyl group.

[0160] In formulas (1) to (4), R 6 , R 7 , R 8 , R 9 and R 10 Each independently represents an electron-withdrawing substituent, an electron-donating substituent or a hydrogen atom. Examples of the electron-withdrawing substituent include an acyl group having 2 to 5 carbon atoms, an alkoxycarbonyl group having 2 to 5 carbon atoms, a carbamoyl group having 2 to 5 carbon atoms, an acyloxy group having 2 to 5 carbon atoms, an acylamino group having 2 to 5 carbon atoms, an alkoxycarbonylamino group having 2 to 5 carbon atoms, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, an alkylsulfanyl group having 1 to 4 carbon atoms, an alkylsulfonyl group having 1 to 4 carbon atoms, an arylsulfonyl group having 6 to 10 carbon atoms, a nitro group, a trifluoromethyl group and a cyano group, preferably an acetyl group, a methoxycarbonyl group, a methylcarbamoyl group, an acetoxy group, an acetamido group, a methoxycarbonylamino group, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a methylsulfanyl group, a benzenesulfonyl group, a nitro group, a trifluoromethyl group and a cyano group.

[0161] The electron-donating substituent may be an alkyl group having 1 to 4 carbon atoms, and preferred examples thereof include methyl, ethyl, propyl, isopropyl and tert-butyl. 7 or R 8 The electron-withdrawing position is at the para and ortho positions, i.e., R 6 , R 9 or R 10Examples of the electron-donating substituent include an alkoxy group having 1 to 4 carbon atoms, an aryl group having 6 to 10 carbon atoms and an aryloxy group having 6 to 10 carbon atoms, and preferred examples thereof include methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, phenyl and phenoxy.

[0162] As a more preferred embodiment of the present invention, it is more preferred that in formulas (1) to (4), m represents 0, and R 1 and R 2 represents a hydrogen atom, R 3 , R 4 , R 5 and R 11 represents a hydrogen atom or a methyl group having 1 carbon atom, and R 3 , R 4 and R 5 represents a hydrogen atom, and R 11 Represents methyl.

[0163] Next, a method for producing an acetal-type releasable polyoxyethylene derivative according to the present invention will be described. In order to produce the acetal-type releasable polyoxyethylene derivative according to the present invention, the following steps are performed: a coupling step of coupling the polyoxyethylene derivative with a hydroxybenzaldehyde derivative to obtain a coupling product represented by the following formula (5) or (6); an acetalization step of, after the above coupling step, coupling the above coupling product represented by the above formula (5) or (6) with a hydroxymethyl group at the 2-position and a substituent (-CH=CB) at the 4-position or the 6-position; 1 ) m C(R 1 )(R 2 )-OH(B 1 ,m,R 1 and R 2 as described above) under acidic conditions to obtain an acetal structure; and a leaving group structure introduction step, after the acetalization step, the leaving group structure (-OC(O)E 1 ) is introduced into the terminal of the above-mentioned substituent at the 4-position or 6-position.

[0164] [Chemical formula 25]

[0165]

[0166] [Chemical formula 26]

[0167]

[0168] (In formula (5) or (6), P 1 ,w,R 6 , R 7 , R 8 , R9 and R 10 As described above.)

[0169] The coupling step of the polyoxyethylene derivative and the hydroxybenzaldehyde derivative is a step of obtaining a coupling product of formula (5) or (6) through a reaction step represented by Reaction 1-1 or Reaction 1-2, and a purification step may be performed after the reaction step.

[0170] (Reaction 1-1)

[0171] [Chemical formula 27]

[0172]

[0173] (Reaction 1-2)

[0174] [Chemical formula 28]

[0175]

[0176] The polyoxyethylene derivative used in the coupling reaction is a compound represented by formula (11), and in formula (11), P 1 The detailed definitions of and w are the same as above, and E 2 represents a leaving group or a hydrogen atom. The leaving group is not particularly limited as long as it is a group having a reaction in a coupling reaction, and examples thereof include a chloro group, a bromo group, an iodo group, a methanesulfonate group, a toluenesulfonate group, a chloromethanesulfonate group, and the like, preferably a methanesulfonate group or a toluenesulfonate group, and more preferably a methanesulfonate group. The hydroxybenzaldehyde derivative is a compound represented by formula (12) or (13), wherein R 6 To R 10 The detailed definition of is the same as above.

[0177] When E in formula (11) 2 When it represents a leaving group, reaction 1-1 or reaction 1-2 is a coupling reaction of the compound of formula (11) and a hydroxybenzaldehyde derivative in an aprotic solvent or in the absence of a solvent in the presence of an organic base or an inorganic base, the aprotic solvent is, for example, toluene, benzene, xylene, acetonitrile, ethyl acetate, diethyl ether, tert-butyl methyl ether, tetrahydrofuran, chloroform, dichloromethane, dimethyl sulfoxide, dimethylformamide or dimethylacetamide, the organic base is, for example, triethylamine, N-methylmorpholine, potassium tert-butoxide or sodium hexamethyldisilazane, the inorganic base is, for example, potassium carbonate, potassium hydroxide or sodium hydride. The ratio of the hydroxybenzaldehyde derivative, organic base and inorganic base used is not particularly limited, but is preferably equimolar or more relative to the chemically reactive functional groups of the compound of formula (11). The organic base can also be used as a solvent.

[0178] When E in formula (11) 2When represents a hydrogen atom, reaction 1-1 or reaction 1-2 is a coupling reaction of the compound of formula (11) with a hydroxybenzaldehyde derivative in the presence of an azo reagent such as diethyl azodicarboxylate or diisopropyl azodicarboxylate and a phosphine such as triphenylphosphine, tri-n-octylphosphine or tributylphosphine in an organic solvent such as tetrahydrofuran, dioxane or dichloromethane. The ratio of the hydroxybenzaldehyde derivative, the azo reagent and the phosphine used is not particularly limited, but is preferably an equimolar or greater ratio relative to the chemically reactive functional group of the compound of formula (11).

[0179] After the reaction steps of reaction 1-1 and reaction 1-2, impurities produced as by-products in the reaction, residual compounds not consumed in the reaction, and the base catalyst are preferably removed by a purification step, and the purification method is not particularly limited, and purification can be performed by extraction, recrystallization, adsorption treatment, reprecipitation, column chromatography, supercritical extraction, etc.

[0180] After the coupling step, the coupling product represented by formula (5) or (6) is reacted with a hydroxymethyl group at the 2-position and a substituent (-CH=CB) at the 4-position or the 6-position under acidic conditions. 1 ) m C(R 1 )(R 2 )-OH(B 1 ,m,R 1 , R 2 The acetalization step of the phenol reaction as described above) is a step of obtaining an acetal structure represented by formula (15), (16), (18) or (19) through a reaction step represented by any one of reactions 2-1 to 2-4, and a purification step may be performed after the reaction step.

[0181] (Reaction 2-1)

[0182] [Chemical formula 29]

[0183]

[0184] (Reaction 2-2)

[0185] [Chemical formula 30]

[0186]

[0187] (Reaction 2-3)

[0188] [Chemical formula 31]

[0189]

[0190] (Reaction 2-4)

[0191] [Chemical formula 32]

[0192]

[0193] In equations (14) to (19), P 1 , B 1 ,m,R 1 , R 2 , R 3 , R 4 , R 5 and R 11 The details are the same as those in the description of the acetal-type releasable polyoxyethylene derivative described above.

[0194] Each of reactions 2-1 to 2-4 is a step of reacting a coupling product represented by formula (5) or formula (6) with a phenol represented by formula (14) or (17) in an aprotic solvent or in the absence of a solvent in the presence of an acid catalyst, such as toluene, benzene, xylene, acetonitrile, ethyl acetate, diethyl ether, tert-butyl methyl ether, tetrahydrofuran, chloroform, dichloromethane, dimethyl sulfoxide, dimethylformamide or dimethylacetamide to obtain an acetal structure represented by formula (15), (16), (18) or (19). The acid catalyst may be either an organic acid or an inorganic acid and is not particularly limited, and specific examples thereof include p-toluenesulfonic acid, pyridinium p-toluenesulfonate, methanesulfonic acid, 10-camphorsulfonic acid, hydrogen chloride, iodine, ammonium chloride, oxalic acid and boron trifluoride ether complex. In addition, a dehydrating agent may be added to the reaction system to remove water molecules produced in the reaction, and the type of the dehydrating agent is not particularly limited as long as it does not interfere with the reaction, and the dehydrating agent includes sodium sulfate, magnesium sulfate, alumina, silica gel and molecular sieves, preferably molecular sieves.

[0195] After the steps of reactions 2-1 to 2-4, impurities produced as by-products in the reaction, residual compounds not consumed in the reaction, and the base catalyst are preferably removed by a purification step, and the purification method is not particularly limited, and purification can be performed by extraction, recrystallization, adsorption treatment, reprecipitation, column chromatography, supercritical extraction, and the like.

[0196] In particular, between the acetalization step and the step of introducing a leaving group structure to the hydroxyl group, a deprotection step of deprotecting the amino group protected by the protecting group in the coupling product of formula (5) and (6) and a step of introducing a group capable of reacting with a biological functional molecule into the deprotected amino group after the deprotection step can be provided. The conditions of the deprotection step of the protecting group and the step of introducing a group capable of reacting with a biological functional molecule into the deprotected amino group can be found in many general textbooks. The deprotection step can be performed, for example, according to "Wuts, PGM; Greene, TW "Protective Groups in Organic Synthesis", 4th edition; Wiley Interscience: New York, 2007", and the step of introducing a group capable of reacting with a biological functional molecule into the deprotected amino group can be performed, for example, according to "Greg T. Hermanso, Bioconjugation Technology, 3rd edition".

[0197] The step of introducing a leaving group structure to replace the terminal hydroxyl group after the above-mentioned acetalization step or the step of introducing a group capable of reacting with a biological functional molecule into the deprotected amino group is a step of converting the hydroxyl group in the polyoxyethylene derivative represented by formula (15), (16), (18) or (19) into a succinimidyloxycarbonyl group, a phthalimidocarbonyloxy group, a 4-nitrophenoxycarbonyl group, a 1-imidazolylcarbonyloxy group, a pentafluorophenoxycarbonyloxy group, a benzotriazole-1-acyloxycarbonyl group or a 7-azabenzotriazole-1-yloxycarbonyl group, and a purification step may be performed after the reaction step.

[0198] The conversion of the hydroxyl group is carried out by condensing the polyoxyethylene derivative represented by the formula (15), (16), (18) or (19) with a reagent for conversion into each leaving group as described in Table 1, for example, in an aprotic solvent or in the absence of a solvent, and in the presence of an organic base or an inorganic base, such as toluene, benzene, xylene, acetonitrile, ethyl acetate, diethyl ether, tert-butyl methyl ether, tetrahydrofuran, chloroform, dichloromethane, dimethyl sulfoxide, dimethylformamide or dimethylacetamide, an organic base such as triethylamine, N-methylmorpholine, pyridine or 4-dimethylaminopyridine, an inorganic base such as sodium carbonate, sodium bicarbonate, sodium acetate or potassium carbonate. The ratio of the reagent and the base catalyst described in Table 1 to be used is not particularly limited, and is preferably equimolar or more relative to the hydroxyl group of the polyoxyethylene derivative of the formula (15), (16), (18) or (19). The reagents shown in Table 1 may be commercially available products or may be prepared by known reactions.

[0199] [Table 1]

[0200]

[0201] After the reaction step of the leaving group structure introduction step, it is preferred to remove impurities produced as by-products in the reaction, residual compounds not consumed in the reaction, and the base catalyst by a purification step, and the purification method is not particularly limited, and purification can be performed by extraction, recrystallization, adsorption treatment, reprecipitation, column chromatography, supercritical extraction, and the like.

[0202] By making the -OC(O)E of the acetal-type releasable polyethylene glycol derivative 1 The group reacts with the amino group in the biofunctional molecule to obtain the acetal-type releasable polyoxyethylene conjugate according to the present invention, and it is represented by the following formula (7), (8), (9) or (10).

[0203] [Chemical formula 33]

[0204]

[0205] [Chemical formula 34]

[0206]

[0207] [Chemical formula 35]

[0208]

[0209] [Chemical formula 36]

[0210]

[0211] In equations (7), (8), (9) and (10),

[0212] B 2 represents a hydrogen atom or -C(R 1 )(R 2 )OC(O)NHD 1 ,

[0213] D 1 represents a residue obtained by removing an amino group constituting a carbamate bond from an amino group contained in a biofunctional molecule,

[0214] P 2 It refers to a polyoxyethylene derivative having a dehydroxylation group, or a combination of a biofunctional molecule and a polyoxyethylene derivative having a dehydroxylation group,

[0215] w represents an integer from 1 to 8,

[0216] R 1 , R 2 , R 3 , R 4 , R 5 and R 11each independently represents a hydrocarbon group having 1 to 10 carbon atoms or a hydrogen atom,

[0217] R 6 , R 7 , R 8 , R 9 and R 10 each independently represents an electron-withdrawing substituent, an electron-donating substituent or a hydrogen atom, and

[0218] m represents 0 or 1.

[0219] In equations (7) to (10), R 1 To R 11 The details of and m are the same as above.

[0220] In equations (7) to (10), B 2 represents a hydrogen atom or -C(R 1 )(R 2 )OC(O)NHD 1 , and preferably represents a hydrogen atom.

[0221] In equations (7) to (10), D 1 It indicates a residue obtained by removing an amino group constituting a carbamate bond from an amino group contained in a biofunctional molecule.

[0222] The biofunctional molecule is not particularly limited as long as it is a substance that participates in the diagnosis, cure, relief, treatment or prevention of human or other animal diseases. Specific examples thereof include proteins, peptides, nucleic acids, cells and viruses, etc., and preferred examples of proteins or peptides include hormones, cytokines, antibodies, aptamers and enzymes, etc.

[0223] More specifically, examples of cytokines include immunomodulatory type I, II and III interferons, interleukins, tumor necrosis factors and their receptor antagonists. Examples of growth factors include erythropoietin as a hematopoietic factor and granulocyte colony stimulating factor (GCSF) as a stimulatory factor, and examples of coagulation factors include factor V, factor VII, factor VIII, factor IX, factor X and factor XII. Examples of hormones include calcitonin, insulin and its analogs, exenatide, GLP-1, somatostatin and human growth hormone. Examples of antibodies include full-length antibodies, examples of antibody fragments include Fab and svFV, examples of aptamers include DNA aptamers and RNA aptamers, and examples of enzymes include superoxide dismutase and uricase.

[0224] Examples of suitable proteins include interferon, interleukin, erythropoietin, GCSF, factor VIII, factor IX, human growth hormone and antibody fragments, more preferably human growth hormone, interferon, GCSF, erythropoietin or antibody fragments (particularly Fab).

[0225] Examples of suitable peptides include insulin, bivalirudin, teriparatide, exenatide, enfuvirtide, degarelix, mifepristone, nesiritide, goserelin, glatiramer, octreotide, lanreotide, icatibant, zicotinib, pramlintide, romiplostim, calcitonin, oxytocin, leuprolide and glucagon, more preferably insulin, exenatide and calcitonin (especially salmon calcitonin).

[0226] In equations (7) to (10), P 2 It refers to a polyoxyethylene derivative having a dehydroxylated group, or a combination of a polyoxyethylene ether derivative having a dehydroxylated group and a biofunctional molecule.

[0227] A detailed description of the polyoxyethylene derivatives having a dehydroxylated group and the P of the acetal-type releasable polyoxyethylene derivatives 1 same.

[0228] The combination of the polyoxyethylene derivative with a dehydroxylated group and a biofunctional molecule is an acetal-type P-type polyoxyethylene derivative that can release 1 X 1 D 2 substituted group, and D 2 The group formed by the reaction of the group capable of reacting with the biofunctional molecule with the biofunctional molecule. Details of the group capable of reacting with the biofunctional molecule and the acetal-type releasable polyoxyethylene derivative X 1 The details are the same as those of the present invention, and the biofunctional molecule is not particularly limited as long as it is a substance involved in the diagnosis, cure, alleviation, treatment or prevention of human or other animal diseases. Specific examples thereof include proteins, peptides, nucleic acids, cells and viruses, and preferred examples of proteins or peptides include hormones, cytokines, antibodies, aptamers and enzymes.

[0229] D 2 Suitable examples of the biofunctional molecules include targeted biofunctional molecules such as antibodies and aptamers, examples of antibodies include antibody fragments such as Fab, Fab' and F(ab')2, and examples of aptamers include peptide aptamers, RNA aptamers and DNA aptamers.

[0230] The method for making the acetal-type releasable polyoxyethylene conjugate of the present invention will now be described. In order to make the polyoxyethylene conjugate of the present invention, the following steps are performed: a coupling step, in which the acetal-type polyoxyethylene derivative is reacted with a biofunctional molecule in a neutral or alkaline buffer to obtain a polyoxyethylene conjugate, wherein the neutral or alkaline buffer may contain a water-soluble organic solvent such as acetonitrile, dimethyl sulfoxide or N,N-dimethylformamide, etc.; and a purification step, in which unreacted polyoxyethylene derivatives, biofunctional molecules or by-products are removed under alkaline conditions after the coupling step. Neutral or alkaline refers to a pH of 6.5 to 11.0, preferably a pH of 7.0 to 10.5, more preferably a pH of 7.0 to 10.0, and particularly preferably a pH of 7.0 to 9.0.

[0231] A neutral or alkaline buffer is an aqueous solution with a buffering effect that mitigates the effects of small amounts of acid or base added externally or changes in concentration through dilution, thereby maintaining the pH (hydrogen ion index) at a nearly constant neutral or alkaline level.

[0232] A water-soluble organic solvent may also be added to the buffer. In this case, examples of the water-soluble organic solvent include methanol, ethanol, propanol, isopropanol, tetrahydrofuran, acetone, acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, triethylamine, pyridine and hexamethylphosphoric triamide, preferably methanol, ethanol, propanol, isopropanol, tetrahydrofuran, acetone, acetonitrile, dimethyl sulfoxide or N,N-dimethylformamide, and more preferably acetonitrile, dimethyl sulfoxide and N,N-dimethylformamide.

[0233] Examples of specific methods for the purification step performed after the coupling step include ion exchange chromatography, gel filtration chromatography, hydrophobic interaction chromatography, reverse phase chromatography, affinity chromatography and the like.

[0234] In the purification step, unreacted polyoxyethylene derivatives, biofunctional molecules or by-products can be removed under neutral or alkaline conditions where the acetal structure in the acetal-type releasable polyoxyethylene conjugate is not easily hydrolyzed, and neutral or alkaline conditions refer to pH 6.5 to 11.0, preferably pH 7.0 to 10.5, more preferably pH 7.0 to 10.0, and particularly preferably pH 7.0 to 9.0.

[0235] Example

[0236] The present invention will be described in more detail below based on Examples, but the present invention is not limited to the following Examples.

[0237] In the following examples, 1 H-NMR was obtained by JNM-ECP400 or JNM-ECA600 manufactured by JEOL Ltd. The acetal type releasable polyoxyethylene conjugate obtained was measured by liquid chromatography (GPC and HPLC). The liquid chromatography system used was "HLC-8320GPC EcoSEC" manufactured by Tosoh Corporation for GPC and "Thermo Ultimate 3000" manufactured by HPLC for ThermoFisher Scientific.

[0238] (Example 1-1)

[0239] SUNBRIGHT MEH-20T (40g, 2.0mmol), toluene (120g) and 2,6-di-tert-butyl-p-cresol (8mg) manufactured by NOF Corporation were added to a 300mL four-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer, a Dean-Stark tube and a cooling tube, and water was removed by azeotropic removal with toluene. After cooling to 45°C, chloroform (200g) was added, then cooled to 25°C, and 4-hydroxybenzaldehyde (977mg, 8.0mmol) and triphenylphosphine (2.10g, 8.0mmol) were added. After stirring for a period of time, diisopropyl azodicarboxylate (1.51g, 7.0mmol) was added three times so that the internal temperature did not exceed 35°C. After reacting for 1 hour at 25°C, methanol (224mg, 7.0mmol) was added, and the mixture was stirred for 30 minutes, and then distilled under reduced pressure to remove the solvent. The residue is dissolved in ethyl acetate (320g), and hexane (240g) is added to cause crystallization, followed by suction filtration to obtain crystal. In addition, the crystal obtained is dissolved in ethyl acetate (320g) containing 2,6-di-tert-butyl-p-cresol (64mg), and hexane (16g) is added subsequently to repeat the crystallization operation to remove low molecular weight impurities. The crystal is washed with hexane (160g), filtered, and dried under reduced pressure to obtain the compound of formula (20).

[0240] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0241] 3.38(3H, s, -(OCH2CH2) n OC H 3), 3.52 to 4.23 (m, - (OC H 2C H 2) n -), 7.03(2H, d, arom.H ), 7.83(2H, d,arom.H ), 9.89(1H, s, -CO H )

[0242] Number average molecular weight (Mn): 20,451

[0243] [Chemical formula 37]

[0244]

[0245] (Example 1-2)

[0246] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with a compound of formula (20) (1.0 g, 0.05 mmol), 2,4-bis(hydroxymethyl)-p-cresol (336 mg, 2.0 mmol), tetrahydrofuran (5.0 g) and 2,6-di-tert-butyl-p-cresol (1.1 mg), and after dissolution, 5A molecular sieves (1.0 g) and p-toluenesulfonic acid monohydrate (11.4 mg, 0.06 mmol) were added, and reacted at 40° C. for 4 hours. N-methylmorpholine (12.1 mg, 0.12 mmol) was added and stirred for a period of time, and then filtered, and the filtrate was diluted with chloroform (10 g). After repeated washing with 20% brine (10 g) of pH 12, the organic layer was dried over anhydrous sodium sulfate and filtered, and distilled under reduced pressure to remove the solvent. The residue was dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and crystallized by adding hexane (66 g), followed by suction filtration to obtain crystals. In addition, the obtained crystals were dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and hexane (66 g) was subsequently added to repeat the crystallization operation to remove low molecular weight impurities, and then dried under reduced pressure to obtain a compound of formula (21).

[0247] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0248] 2.27(1H, t, -O H ), 2.36(3H, s, -C H 3), 3.38 (3H, s, -(OCH2CH2) n OC H 3), 3.52 to 4.17 (m, - (OC H 2C H 2) n -), 4.68 (2H, dd, -C H 2OH), 4.94 (1H, d, -C H 2O-), 5.15(1H, d, -C H2O-), 5.96(1H, s, -C H <), 6.77(1H, s, arom.H ), 6.97(2H, d, arom.H ), 7.04(1H, s, arom.H ), 7.50(2H, d, arom.H )

[0249] Number average molecular weight (Mn): 20,435

[0250] [Chemical formula 38]

[0251]

[0252] (Example 1-3)

[0253] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer was added with a compound of formula (21) (250 mg, 0.0125 mmol) and dichloromethane (3.6 g) and dissolved, followed by pyridine (23.7 mg, 0.30 mmol) and p-nitrophenyl chloroformate (40.3 mg, 0.20 mmol), and reacted at 25 ° C for 3 hours. After repeated washing with 20% brine (2.5 g) at pH 12 to remove some impurities, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and crystallized by adding hexane (66 g), followed by suction filtration to obtain crystals. Furthermore, the obtained crystals were dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and then hexane (66 g) was added to crystallize, followed by filtration and drying under reduced pressure, and then the compound of formula (22) was obtained.

[0254] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0255] 2.31(3H, s, -C H 3), 3.38 (3H, s, -(OCH2CH2) n OC H 3), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.96(1H, d, -C H 2O-), 5.16(1H, d, -C H 2O-), 5.35 (2H, dd, -C H 2OCO-), 5.98 (1H, s, -C H <), 6.87(1H, s,arom.H ), 6.94(2H, d, arom.H ), 7.11(1H, s, arom.H ), 7.26 to 7.29 (2H, m, arom.H ), 7.52(2H, d, arom.H ), 8.24(2H, d, arom.H )

[0256] Number average molecular weight (Mn): 20,204

[0257] [Chemical formula 39]

[0258]

[0259] (Example 2-1)

[0260] SUNBRIGHT MEH-20T (40g, 2.0mmol), toluene (120g) and 2,6-di-tert-butyl-p-cresol (8mg) manufactured by NOF Corporation were added to a 300mL four-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer, a Dean-Stark tube and a cooling tube, and water was removed by azeotropic removal with toluene. After cooling to 45°C, chloroform (200g) was added, then cooled to 25°C, and 3-fluoro-4-hydroxybenzaldehyde (1.12g, 8.0mmol) and triphenylphosphine (2.62g, 10.0mmol) were added. After stirring for a period of time, diisopropyl azodicarboxylate (1.84g, 8.6mmol) was added three times so that the internal temperature did not exceed 35°C. After reacting for 2 hours at 25°C, methanol (276mg, 8.6mmol) was added, and the mixture was stirred for 30 minutes, and then distilled under reduced pressure to remove the solvent. The residue is dissolved in ethyl acetate (320g), and hexane (240g) is added to cause crystallization, followed by suction filtration to obtain crystal. In addition, the crystal obtained is dissolved in ethyl acetate (320g) containing 2,6-di-tert-butyl-p-cresol (64mg), and hexane (160g) is added subsequently to repeat the crystallization operation to remove low molecular weight impurities. The crystal is washed with hexane (160g), filtered, and dried under reduced pressure to obtain the compound of formula (23).

[0261] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0262] 3.38(3H, s, -(OCH2CH2) n OC H 3), 3.52 to 4.30 (m, - (OC H 2C H 2) n-), 7.13(1H, t, -C H <), 7.60 to 7.65 (2H, m, arom.H ), 9.86(1H, s, -CO H )

[0263] Number average molecular weight (Mn): 20,201

[0264] [Chemical formula 40]

[0265]

[0266] (Example 2-2)

[0267] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with a compound of formula (23) (1.0 g, 0.05 mmol), 2,4-bis(hydroxymethyl)-p-cresol (336 mg, 2.0 mmol), tetrahydrofuran (5.0 g) and 2,6-di-tert-butyl-p-cresol (1.1 mg), and after decomposition, 5A molecular sieves (1.0 g) and p-toluenesulfonic acid monohydrate (11.4 mg, 0.06 mmol) were added, and the reaction was carried out at 40° C. for 4 hours. N-methylmorpholine (12.1 mg, 0.12 mmol) was added and stirred for a period of time, and then filtered, and the filtrate was diluted with chloroform (10 g). After repeated washing with 20% brine (10 g) of pH 12, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and crystallized by adding hexane (66 g), followed by suction filtration to obtain crystals. In addition, the obtained crystals were dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and hexane (66 g) was then added to repeat the crystallization operation to remove low molecular weight impurities, and then dried under reduced pressure to obtain a compound of formula (24).

[0268] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0269] 2.20(1H, t, -O H ), 2.29(3H, s, -C H 3), 3.38 (3H, s, -(OCH2CH2) n OC H 3), 3.52 to 4.24 (m, - (OC H 2C H 2) n -), 4.68 (2H, dd, -C H2OH), 4.94 (1H, d, -C H 2O-), 5.14 (1H, d, -C H 2O-), 5.93(1H, s, -C H <), 6.77(1H, s, arom.H ), 7.04(1H, t, arom.H ), 7.06(1H, s, arom.H ), 7.34 to 7.26 (2H, m, arom.H )

[0270] Number average molecular weight (Mn): 20,445

[0271] [Chemical formula 41]

[0272]

[0273] (Example 2-3)

[0274] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer was added with a compound of formula (24) (180 mg, 0.009 mmol) and dichloromethane (2.4 g) and dissolved, and then pyridine (17.1 mg, 0.216 mmol) and p-nitrophenyl chloroformate (29.0 mg, 0.144 mmol) were added, and reacted at 25 ° C for 3 hours. After repeated washing with 20% saline (1.8 g) at pH 12 to remove some impurities, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and crystallized by adding hexane (66 g), and then filtered by suction to obtain crystals. Furthermore, the obtained crystals were dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and then hexane (66 g) was added to crystallize, followed by filtration and drying under reduced pressure, and then the compound of formula (25) was obtained.

[0275] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0276] 2.32(3H, s, -C H 3), 3.38 (3H, s, -(OCH2CH2) n OC H 3), 3.52 to 4.24 (m, - (OC H 2C H 2) n -), 4.96(1H, d, -C H 2O-), 5.15(1H, d, -CH 2O-), 5.34 (2H, dd, -C H 2OCO-), 5.96(1H, s, -C H <), 6.87(1H, s, arom.H ), 7.01(1H, t, arom.H ), 7.12(1H, s, arom.H ), 7.26 to 7.36 (4H, m, arom.H ), 8.26(2H, d, arom.H )

[0277] Number average molecular weight (Mn): 20,298

[0278] [Chemical formula 42]

[0279]

[0280] (Example 3-1)

[0281] SUNBRIGHT MEH-20T (40g, 2.0mmol), toluene (120g) and 2,6-di-tert-butyl-p-cresol (8mg) manufactured by NOF Corporation were added to a 300mL four-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer, a Dean-Stark tube and a cooling tube, and water was removed by azeotropic removal with toluene. After cooling to 45°C, chloroform (200g) was added, and then cooled to 25°C, and 4-hydroxy-2-methoxybenzaldehyde (1.22g, 8.0mmol) and triphenylphosphine (2.62g, 10.0mmol) were added. After stirring for a period of time, diisopropyl azodicarboxylate (1.84g, 8.6mmol) was added three times so that the internal temperature did not exceed 35°C. After reacting for 2 hours at 25°C, methanol (276mg, 8.6mmol) was added, and the mixture was stirred for 30 minutes, and then distilled under reduced pressure to remove the solvent. The residue is dissolved in ethyl acetate (320 g), and hexane (240 g) is added to cause crystallization, followed by suction filtration to obtain crystals. The obtained crystals are dissolved in ethyl acetate (320 g) containing 2,6-di-tert-butyl-p-cresol (64 mg), and hexane (160 g) is added to repeat the crystallization operation to remove low molecular weight impurities. The crystals are washed with hexane (160 g), filtered, and dried under reduced pressure to obtain the compound of formula (26).

[0282] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0283] 3.38(3H, s, -(OCH2CH2) n OC H3), 3.52 to 4.21 (m, - (OC H 2C H 2) n -), 6.50(1H, d, arom.H ), 6.55(1H, dd, arom.H ), 7.79(2H, d, arom.H ), 10.3(1H, s, -CO H )

[0284] Number average molecular weight (Mn): 20,216

[0285] [Chemical formula 43]

[0286]

[0287] (Example 3-2)

[0288] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with a compound of formula (26) (1.0 g, 0.05 mmol), 2,4-bis(hydroxymethyl)-p-cresol (336 mg, 2.0 mmol), tetrahydrofuran (5.0 g) and 2,6-di-tert-butyl-p-cresol (1.1 mg), and after decomposition, 5A molecular sieves (1.0 g) and p-toluenesulfonic acid monohydrate (11.4 mg, 0.06 mmol) were added, and reacted at 40° C. for 4 hours. N-methylmorpholine (12.1 mg, 0.12 mmol) was added and stirred for a period of time, and then filtered, and the filtrate was diluted with chloroform (10 g). After repeated washing with 20% brine (10 g) of pH 12 to remove some low molecular weight impurities, the organic layer was dried over anhydrous sodium sulfate and filtered, and distilled under reduced pressure to remove the solvent. The residue was dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and crystallized by adding hexane (66 g), followed by suction filtration to obtain crystals. In addition, the obtained crystals were dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and hexane (66 g) was then added to repeat the crystallization operation to remove low molecular weight impurities, and then dried under reduced pressure to obtain a compound of formula (27).

[0289] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0290] 2.28 (3H, s, -C H3 ), 2.84(1H, dd, -O H ), 3.38(3H, s, -(OCH2CH2) n OC H3), 3.52 to 4.17 (m, - (OC H2 C H2 ) n -), 4.47(1H, dd, -C H2 OH), 4.75(1H, dd, -C H2 OH), 4.98 (1H, d, -C H2 O-), 5.17 (1H, d, -C H2 O-), 6.20 (1H, s, -C H <), 6.57 to 6.55 (2H, m, arom.H ), 6.78(1H, s, arom.H ), 6.97(1H, s, arom.H ), 7.58(2H, d, arom.H )

[0291] Number average molecular weight (Mn): 20,215

[0292] [Chemical formula 44]

[0293]

[0294] (Example 3-3)

[0295] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer was added with a compound of formula (27) (300 mg, 0.015 mmol) and dichloromethane (4.0 g) and dissolved, and then pyridine (28.5 mg, 0.360 mmol) and p-nitrophenyl chloroformate (48.4 mg, 0.240 mmol) were added, and reacted at 25 ° C for 3 hours. After repeated washing with 20% saline (3.0 g) at pH 12 to remove some low molecular weight impurities, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and crystallized by adding hexane (66 g), and then filtered by suction to obtain crystals. Furthermore, the obtained crystals were dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and then hexane (66 g) was added to crystallize, followed by filtration and drying under reduced pressure, and then the compound of formula (28) was obtained.

[0296] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0297] 2.31(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OCH3 ), 3.52 to 4.17 (m, - (OC H2 C H2 ) n -), 4.93(1H, d, -C H2 O-), 5.18 (1H, d, -C H2 O-), 5.33 (2H, dd, -C H2 OCO-), 6.26 (1H, s, -C H <), 6.52 to 6.54 (2H, m, arom.H ), 6.87(1H, s, arom.H ), 7.10(1H, s, arom.H ), 7.26 to 7.27 (2H, m, arom.H ), 7.59(1H, d, arom.H ), 8.22(2H, d, arom.H )

[0298] Number average molecular weight (Mn): 20,315

[0299] [Chemical formula 45]

[0300]

[0301] (Example 4-1)

[0302] SUNBRIGHT GL2-400HO (10g, 0.25mmol), toluene (30g) and 2,6-di-tert-butyl-p-cresol (2mg) manufactured by NOF Corporation were added to a 300mL four-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer, a Dean-Stark tube and a cooling tube, and water was removed by azeotropic removal with toluene. After cooling to 45°C, chloroform (50g) was added, and then cooled to 25°C, and 4-hydroxybenzaldehyde (244mg, 2.0mmol) and triphenylphosphine (524mg, 2.0mmol) were added. After stirring for a period of time, diisopropyl azodicarboxylate (376g, 1.75mmol) was added three times so that the internal temperature did not exceed 35°C. After reacting for 2 hours at 25°C, methanol (56mg, 1.75mmol) was added, and the mixture was stirred for 30 minutes, and then distilled under reduced pressure to remove the solvent. The residue is dissolved in ethyl acetate (80g), and hexane (60g) is added to cause crystallization, followed by suction filtration to obtain crystal. In addition, the crystal obtained is dissolved in ethyl acetate (80g) containing 2,6-di-tert-butyl-p-cresol (16mg), and hexane (40g) is added subsequently to repeat the crystallization operation to remove low molecular weight impurities. The crystal is washed with hexane (40g), filtered, and dried under reduced pressure to obtain the compound of formula (29).

[0303] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0304] 3.38 (6H, s, -(OCH2CH2) n OC H3 ), 3.52 to 3.92 (m, - (OC H2 C H2 ) n -), 4.13(1H, dd, -C H2 O-), 4.21(1H, dd, -C H2 O-), 7.03 (2H, d, arom.H ), 7.83(2H, d, arom.H ), 9.89(1H, s, -CO H )

[0305] Number average molecular weight (Mn): 38,947

[0306] [Chemical formula 46]

[0307]

[0308] (Example 4-2)

[0309] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with a compound of formula (29) (1.0 g, 0.025 mmol), 2,4-bis(hydroxymethyl)-p-cresol (336 mg, 2.0 mmol), tetrahydrofuran (5.0 g) and 2,6-di-tert-butyl-p-cresol (1.1 mg), and after dissolution, 5A molecular sieves (1.0 g) and p-toluenesulfonic acid monohydrate (17.1 mg, 0.09 mmol) were added, and reacted at 40° C. for 4 hours. N-methylmorpholine (12.1 mg, 0.12 mmol) was added and stirred for a period of time, and then filtered, and the filtrate was diluted with chloroform (20 g). After repeated washing with 20% brine (20 g) of pH 12, the organic layer was dried over anhydrous sodium sulfate and filtered, and distilled under reduced pressure to remove the solvent. The residue was dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and crystallized by adding hexane (66 g), followed by suction filtration to obtain crystals. In addition, the obtained crystals were dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and hexane (66 g) was then added to repeat the crystallization operation to remove low molecular weight impurities, and then dried under reduced pressure to obtain a compound of formula (30).

[0310] 1H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0311] 2.29(3H, s, -C H3 ), 2.35(1H, t, -O H ), 3.38(6H, s, -(OCH2CH2) n OC H3 ), 3.52 to 3.91 (m, - (OC H2 C H2 ) n -), 4.07(1H, dd, -C H2 O-), 4.14 (1H, dd, -C H2 O-), 4.68 (2H, dd, -C H2 OH), 4.94 (1H, d, -C H2 O-), 5.15(1H, d, -C H2 O-), 5.96 (1H, s, -C H <), 6.77(1H, s, arom.H ), 6.97(2H, d, arom.H ), 7.04(1H, s, arom.H ), 7.50(2H, d, arom.H )

[0312] Number average molecular weight (Mn): 39,110

[0313] [Chemical formula 47]

[0314]

[0315] (Example 4-3)

[0316] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer was added with a compound of formula (30) (250 mg, 0.00625 mmol) and dichloromethane (3.6 g) and dissolved, then pyridine (11.9 mg, 0.15 mmol) and p-nitrophenyl chloroformate (20.3 mg, 0.10 mmol) were added, and reacted at 25 ° C for 3 hours. After repeated washing with 20% brine (2.5 g) at pH 12 to remove some impurities, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (45 g) containing 2,6-di-tert-butyl-p-cresol (9 mg), and crystallized by adding hexane (33 g), and then filtered by suction to obtain crystals. Furthermore, the obtained crystals were dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (9 mg), and then hexane (33 g) was added to crystallize, followed by filtration and drying under reduced pressure, and then the compound of formula (31) was obtained.

[0317] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0318] 2.29(3H, s, -C H3 ), 3.38(6H, s, -(OCH2CH2) n OC H3 ), 3.52 to 3.91 (m, - (OC H2 C H2 ) n -), 4.07(1H, dd, -C H2 O-), 4.14 (1H, dd, -C H2 O-), 4.94 (1H, d, -C H2 O-), 5.16 (1H, d, -C H2 O-), 5.35(1H, d, -C H2 OCO-), 5.98 (1H, s, -C H <), 6.87(1H, s, arom.H ), 6.94(2H, d, arom.H ), 7.11(1H, s, arom.H ), 7.26 to 7.29 (2H, m, arom.H ), 7.52(2H, d, arom.H ), 8.24(2H, d, arom.H )

[0319] Number average molecular weight (Mn): 39,456

[0320] [Chemical formula 48]

[0321]

[0322] (Example 5-1)

[0323] SUNBRIGHT PTE-200HO (10g, 0.5mmol), toluene (30g) and 2,6-di-tert-butyl-p-cresol (2mg) manufactured by NOF Corporation were added to a 300mL four-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer, a Dean-Stark tube and a cooling tube, and water was removed by azeotropic removal with toluene. After cooling to 45°C, chloroform (50g) was added, and then cooled to 25°C, and 4-hydroxybenzaldehyde (977mg, 8.0mmol) and triphenylphosphine (2.10g, 8.0mmol) were added. After stirring for a period of time, diisopropyl azodicarboxylate (1.51g, 7.0mmol) was added three times so that the internal temperature did not exceed 35°C. After reacting for 1 hour at 25°C, methanol (224mg, 7.0mmol) was added, and the mixture was stirred for 30 minutes, and then distilled under reduced pressure to remove the solvent. Residue is dissolved in ethyl acetate (320g), and hexane (240g) is added to cause crystallization, followed by suction filtration to obtain crystal. In addition, the crystal obtained is dissolved in ethyl acetate (80g) containing 2,6-di-tert-butyl-p-cresol (64mg), and hexane (160g) is added subsequently to repeat crystallization operation to remove low molecular weight impurities. The crystal obtained after washing and filtering with hexane (160g) is filtered, and then dried under reduced pressure to obtain the compound of formula (32).

[0324] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0325] 3.41 to 4.23 (m, - (OC H2 C H2 ) n -), 7.03(8H, d, arom.H ), 7.83(8H, d, arom.H ), 9.89(4H, s, -CO H )

[0326] [Chemical formula 49]

[0327]

[0328] (Example 5-2)

[0329] A 50mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with a compound of formula (32) (1.0 g, 0.05 mmol), 2,4-bis(hydroxymethyl)-p-cresol (1.34 g, 8 mmol), tetrahydrofuran (5.0 g) and 2,6-di-tert-butyl-p-cresol (1.1 mg), and after dissolution, 5A molecular sieves (1.0 g) and p-toluenesulfonic acid monohydrate (45.6 mg, 0.24 mmol) were added, and the reaction was carried out at 40°C for 4 hours. N-methylmorpholine (48.4 mg, 0.48 mmol) was added and stirred for a period of time, and then filtered, and the filtrate was diluted with chloroform (10 g). After repeated washing with 20% brine (10 g) of pH 12, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (360 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and crystallized by adding hexane (264 g), followed by suction filtration to obtain crystals. In addition, the obtained crystals were dissolved in ethyl acetate (360 g) containing 2,6-di-tert-butyl-p-cresol (72 mg), and hexane (264 g) was subsequently added to repeat the crystallization operation to remove low molecular weight impurities, and then dried under reduced pressure to obtain a compound of formula (33).

[0330] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0331] 2.27 (4H, t, -O H ), 2.36(12H, s, -C H3 ), 3.41 to 4.23 (m, - (OC H2 C H2 ) n -), 4.68(8H, dd, -C H2 OH), 4.94 (4H, d, -C H2 O-), 5.15 (4H, d, -C H2 O-), 5.96 (4H, s, -C H <), 6.77(4H, s, arom.H ), 6.97(8H, d, arom.H ), 7.04(4H, s, arom.H ), 7.50(8H, d, arom.H )

[0332] [Chemical formula 50]

[0333]

[0334] (Example 5-3)

[0335] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer was added with a compound of formula (33) (250 mg, 0.0125 mmol) and dichloromethane (3.6 g) and dissolved, then pyridine (94.8 mg, 1.20 mmol) and p-nitrophenyl chloroformate (161 mg, 0.80 mmol) were added, and reacted at 25 ° C for 3 hours. After repeated washing with 20% saline (2.5 g) at pH 12 to remove some low molecular weight impurities, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (360 g) containing 2,6-di-tert-butyl-p-cresol (72 mg), and crystallized by adding hexane (264 g), and then filtered by suction to obtain crystals. Furthermore, the obtained crystals were dissolved in ethyl acetate (360 g) containing 2,6-di-tert-butyl-p-cresol (72 mg), and then hexane (264 g) was added to crystallize, followed by filtration and drying under reduced pressure, and then the compound of formula (34) was obtained.

[0336] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0337] 2.31(12H, s, -C H3 ), 3.41 to 4.23 (m, - (OC H2 C H2 ) n -), 4.96(4H, d, -C H2 O-), 5.16 (4H, d, -C H2 O-), 5.35 (8H, dd, -C H2 OCO-), 5.98 (4H, s, -C H <), 6.87(4H, s, arom.H ), 6.94(8H, d, arom.H ), 7.11(4H, s, arom.H ), 7.26 to 7.29 (8H, m, arom.H ), 7.52(8H, d, arom.H ), 8.24(8H, d, arom.H )

[0338] [Chemical formula 51]

[0339]

[0340] (Example 6-1)

[0341] SUNBRIGHT HGEO-400HO (10 g, 0.25 mmol), toluene (30 g) and 2,6-di-tert-butyl-p-cresol (2 mg) manufactured by NOF Corporation were added to a 300 mL four-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer, a Dean-Stark tube and a cooling tube, and water was removed by azeotropic removal with toluene. After cooling to 45 ° C, chloroform (50 g) was added, and then cooled to 25 ° C, and 4-hydroxybenzaldehyde (977 mg, 8.0 mmol) and triphenylphosphine (2.10 g, 8.0 mmol) were added. After stirring for a period of time, diisopropyl azodicarboxylate (1.51 g, 7.0 mmol) was added three times so that the internal temperature did not exceed 35 ° C. After reacting for 1 hour at 25 ° C, methanol (224 mg, 7.0 mmol) was added, and the mixture was stirred for 30 minutes, and then the solvent was distilled off under reduced pressure. The residue is dissolved in ethyl acetate (320g), and hexane (240g) is added to cause crystallization, followed by suction filtration to obtain crystal. In addition, the crystal obtained is dissolved in ethyl acetate (320g) containing 2,6-di-tert-butyl-p-cresol (64mg), and hexane (160g) is added subsequently to repeat the crystallization operation to remove low molecular weight impurities. The crystal is washed with hexane (160g), filtered, and dried under reduced pressure to obtain the compound of formula (35).

[0342] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0343] 2.98 to 4.23 (m, - (OC H2 C H2 ) n -), 7.03(16H, d, arom.H ), 7.83(16H, d, arom.H ), 9.89(8H, s, -CO H )

[0344] [Chemical formula 52]

[0345]

[0346] (Example 6-2)

[0347] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with a compound of formula (35) (1.0 g, 0.025 mmol), 2,4-bis(hydroxymethyl)-p-cresol (1.34 g, 8.0 mmol), tetrahydrofuran (5.0 g) and 2,6-di-tert-butyl-p-cresol (1.1 mg), and after dissolution, 5A molecular sieves (1.0 g) and p-toluenesulfonic acid monohydrate (45.6 mg, 0.24 mmol) were added, and reacted at 40° C. for 4 hours. N-methylmorpholine (48.4 mg, 0.48 mmol) was added and stirred for a period of time, and then filtered, and the filtrate was diluted with chloroform (10 g). After repeated washing with 20% brine (10 g) of pH 12 to remove some low molecular weight impurities, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (360 g) containing 2,6-di-tert-butyl-p-cresol (72 mg), and crystallized by adding hexane (264 g), followed by suction filtration to obtain crystals. In addition, the obtained crystals were dissolved in ethyl acetate (360 g) containing 2,6-di-tert-butyl-p-cresol (72 mg), and hexane (264 g) was subsequently added to repeat the crystallization operation to remove low molecular weight impurities, and then dried under reduced pressure to obtain a compound of formula (36).

[0348] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0349] 2.27(8H, t, -O H ), 2.36(24H, s, -C H3 ), 2.98 to 4.23 (m, - (OC H2 C H2 ) n -), 4.68(16H, dd, -C H2 OH), 4.94 (8H, d, -C H2 O-), 5.15 (8H, d, -C H2 O-), 5.96 (8H, s, -C H <), 6.77(8H, s, arom.H ), 6.97(16H, d, arom.H ), 7.04(8H, s, arom.H ), 7.50(16H, d, arom.H )

[0350] [Chemical formula 53]

[0351]

[0352] (Example 6-3)

[0353] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer was added with a compound of formula (36) (250 mg, 0.00625 mmol) and dichloromethane (3.6 g) and dissolved, then pyridine (94.8 mg, 1.20 mmol) and p-nitrophenyl chloroformate (161.2 mg, 0.80 mmol) were added, and reacted at 25 ° C for 3 hours. After repeated washing with 20% brine (2.5 g) at pH 12 to remove some low molecular weight impurities, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (360 g) containing 2,6-di-tert-butyl-p-cresol (72 mg), and crystallized by adding hexane (264 g), and then filtered by suction to obtain crystals. Furthermore, the obtained crystals were dissolved in ethyl acetate (360 g) containing 2,6-di-tert-butyl-p-cresol (72 mg), and then hexane (263 g) was added to crystallize, followed by filtration and drying under reduced pressure, and then the compound of formula (37) was obtained.

[0354] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0355] 2.31(24H,s,-C H3 ), 2.98 to 4.23 (m, - (OC H2 C H2 ) n -), 4.96(8H, d, -C H2 O-), 5.16 (8H, d, -C H2 O-), 5.35 (16H, dd, -C H2 OCO-), 5.98 (8H, s, -C H <), 6.87(8H, s, arom.H ), 6.94(16H, d, arom.H ), 7.11(8H, s, arom.H ), 7.26 to 7.29 (16H, m, arom.H ), 7.52(16H, d, arom.H ), 8.24(16H, d, arom.H )

[0356] [Chemical formula 54]

[0357]

[0358] (Example 7-1)

[0359] SUNBRIGHT DKH-20T (20g, 1.0mmol), toluene (60g) and 2,6-di-tert-butyl-p-cresol (4mg) manufactured by NOF Corporation were added to a 300mL four-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer, a Dean-Stark tube and a cooling tube, and water was removed by azeotropic removal with toluene. After cooling to 45°C, chloroform (100g) was added, and then cooled to 25°C, and 4-hydroxybenzaldehyde (977mg, 8.0mmol) and triphenylphosphine (2.10g, 8.0mmol) were added. After stirring for a period of time, diisopropyl azodicarboxylate (1.51g, 7.0mmol) was added three times so that the internal temperature did not exceed 35°C. After reacting for 1 hour at 25°C, methanol (224mg, 7.0mmol) was added, and the mixture was stirred for 30 minutes, and then distilled under reduced pressure to remove the solvent. The residue is dissolved in ethyl acetate (320g), and hexane (240g) is added to cause crystallization, followed by suction filtration to obtain crystal. In addition, the crystal obtained is dissolved in ethyl acetate (320g) containing 2,6-di-tert-butyl-p-cresol (64mg), and hexane (160g) is added to repeat the crystallization operation to remove low molecular weight impurities. The crystal is washed with hexane (160g), filtered, and dried under reduced pressure to obtain the compound of formula (38).

[0360] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0361] 3.52 to 4.23 (m, - (OC H2 C H2 ) n -), 7.03(4H, d, arom.H ), 7.83(4H, d, arom.H ), 9.89(2H, s, -CO H )

[0362] [Chemical formula 55]

[0363]

[0364] (Example 7-2)

[0365] A 50mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with a compound of formula (38) (1.0 g, 0.05 mmol), 2,4-bis(hydroxymethyl)-p-cresol (672 mg, 4.0 mmol), tetrahydrofuran (5.0 g) and 2,6-di-tert-butyl-p-cresol (1.1 mg), and after dissolution, 5A molecular sieves (1.0 g) and p-toluenesulfonic acid monohydrate (22.8 mg, 0.12 mmol) were added, and reacted at 40°C for 4 hours. N-methylmorpholine (24.2 mg, 0.24 mmol) was added and stirred for a period of time, and then filtered, and the filtrate was diluted with chloroform (10 g). After repeated washing with 20% brine (10 g) of pH 12, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (180 g) containing 2,6-di-tert-butyl-p-cresol (36 mg), and crystallized by adding hexane (132 g), followed by suction filtration to obtain crystals. In addition, the obtained crystals were dissolved in ethyl acetate (180 g) containing 2,6-di-tert-butyl-p-cresol (36 mg), and hexane (132 g) was subsequently added to repeat the crystallization operation to remove low molecular weight impurities, and then dried under reduced pressure to obtain a compound of formula (39).

[0366] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0367] 2.27 (2H, t, -O H ), 2.36(6H, s, -C H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.68(4H, dd, -C H2 OH), 4.94 (2H, d, -C H2 O-), 5.15 (2H, d, -C H2 O-), 5.96 (2H, s, -C H <), 6.77(2H, s, arom.H ), 6.97(4H, d, arom.H ), 7.04(2H, s, arom.H ), 7.50(4H, d, arom.H )

[0368] [Chemical formula 56]

[0369]

[0370] (Example 7-3)

[0371] A 50mL three-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer was added with a compound of formula (39) (250mg, 0.0125mmol) and dichloromethane (3.6g) and dissolved, and then pyridine (47.4mg, 0.60mmol) and p-nitrophenyl chloroformate (80.6mg, 0.40mmol) were added, and reacted at 25°C for 3 hours. After repeated washing with 20% saline (2.5g) of pH 12, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (180g) containing 2,6-di-tert-butyl-p-cresol (36mg), and crystallized by adding hexane (132g), and then filtered by suction to obtain crystals. Furthermore, the obtained crystals were dissolved in ethyl acetate (180 g) containing 2,6-di-tert-butyl-p-cresol (36 mg), and then hexane (132 g) was added to crystallize, followed by filtration and drying under reduced pressure, and then the compound of formula (40) was obtained.

[0372] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0373] 2.31(6H, s, -C H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.96(2H, d, -C H2 O-), 5.16 (2H, d, -C H2 O-), 5.35 (4H, dd, -C H2 OCO-), 5.98 (2H, s, -C H <), 6.87(2H, s, arom.H ), 6.94(4H, d, arom.H ), 7.11(2H, s, arom.H ), 7.26 to 7.29 (4H, m, arom.H ), 7.52(4H, d, arom.H ), 8.24(4H, d, arom.H )

[0374] [Chemical formula 57]

[0375]

[0376] (Comparative Example 1-1)

[0377] 3-hydroxybenzaldehyde (2.00g, 16.4mmol), trimethyl orthoformate (3.48g, 32.8mmol) and methyl alcohol (17g) are added in the 50mL three-necked flask equipped with thermometer, nitrogen inlet pipe, agitator and cooling tube, and p-toluenesulfonic acid monohydrate (0.312mg, 1.64mmol) is added subsequently, and reacted 2 hours at 25 ℃.Sodium hydroxide is added and stirred for a period of time, and then distilled under reduced pressure to remove solvent.Residue is dissolved in dichloromethane, washed with the sodium bicarbonate aqueous solution of 5wt%, and then washed with the saline of 25wt%, and dried over anhydrous sodium sulfate organic layer.After filtration, decompression is removed and solvent is removed, to obtain the compound of formula (41).

[0378] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0379] 3.33(6H,s,-OC H3 ), 5.35(1H, s, -C H <), 6.81(1H, d, arom.H ), 6.95(1H, d, arom.H ), 7.23 to 7.26 (1H, m, arom.H )

[0380] [Chemical formula 58]

[0381]

[0382] (Comparative Example 1-2)

[0383] 2,4-bis(hydroxymethyl)phenol (50.0 mg, 0.324 mmol), a compound of formula (41) (217 mg, 1.29 mmol), 2,6-di-tert-butyl-p-cresol (7.14 mg, 0.0324 mmol), anhydrous sodium sulfate (1 g) and cyclopentyl methyl ether (10 g) were added to a 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube, and then p-toluenesulfonic acid monohydrate (4.10 mg, 0.0212 mmol) was added and reacted at 40° C. for 2 hours. N-methylmorpholine was added and stirred for a period of time, and then filtered. After washing with 10 wt % of brine, the organic layer was dried over anhydrous sodium sulfate. After filtering, the solvent was removed under reduced pressure to obtain a compound of formula (42).

[0384] 1 H-NMR (d6-DMSO, internal standard TMS); δ (ppm):

[0385] 4.42 (2H, d, -C H2 OH), 4.93(1H, d, -C H2 O-), 5.10(1H, t, -CH2O H ), 5.15(1H, d, -C H2 O-), 6.01(1H, s, -C H <), 6.80 to 7.21 (7H, m, arom.H ), 9.53(1H, bs,>CO H )

[0386] [Chemical formula 59]

[0387]

[0388] (Comparative Examples 1-3)

[0389] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was charged with a compound of formula (42) (37.0 mg, 0.141 mmol), ME-200MS (α-methyl-ω-[(methylsulfonyl)oxy]poly(ethylene oxide) (705 mg, 0.0353 mmol) manufactured by NOF Corporation, potassium carbonate (97.0 mg, 0.705 mmol) and acetonitrile (3.5 g), and reacted at 80° C. for 4 hours. After filtration, the solvent was removed under reduced pressure, and the residue was dissolved in dichloromethane. After washing with 10 wt % brine, the organic layer was dried over anhydrous sodium sulfate. After filtration, the solvent was removed under reduced pressure, and the residue was dissolved in toluene (50 g). Hexane (50 g) was added to induce crystallization, followed by filtration and drying under reduced pressure to obtain a compound of formula (43).

[0390] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0391] 3.38(3H, s, -OC H3 ), 3.52 to 4.18 (m, - (OC H2 C H2 ) n -), 4.62(2H, s, -C H2 OH), 4.98 (1H, d, -C H2 O-), 5.18 (1H, d, -C H2 O-), 5.95(1H, s, -C H <), 6.87 to 7.34 (7H, m, arom.H )

[0392] [Chemical formula 60]

[0393]

[0394] (Comparative Examples 1-4)

[0395] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with a compound of formula (43) (300 mg, 0.0150 mmol), di(N-succinimidyl) carbonate (46.0 mg, 0.180 mmol), triethylamine (21.0 mg, 0.208 mmol) and dichloromethane (5 g), and reacted at 25 ° C for 12 hours. After filtration, the mixture was washed with 5 wt% of saline and distilled under reduced pressure to remove the solvent in the organic layer. The residue was dissolved in ethyl acetate (6 g), dried over anhydrous sodium sulfate, and then filtered. After adding ethyl acetate (44 g), hexane (50 g) was added to crystallize it, then filtered and dried under reduced pressure to obtain a compound of formula (44).

[0396] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0397] 2.85(4H,s,-COC H2 C H2 CO-), 3.38(3H, s, -OC H3 ), 3.52 to 4.18 (m, - (OC H2 C H2 ) n -), 5.00(1H, d, -C H2 OCH<), 5.18 (1H, d, -C H2 O-), 5.25 (2H, s, -CH 2 OCO-), 5.97 (1H, s, -C H <), 6.96 to 7.35 (7H, m, arom.H )

[0398] [Chemical formula 61]

[0399]

[0400] (Example 8-1)

[0401] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with the compound of formula (20) (1.0 g, 0.05 mmol), 2,4-di(hydroxymethyl)phenol (336 mg, 2.0 mmol) synthesized according to the literature (Freeman, JH; JAm. Chem. Soc. 1952, 74, 6257-6260), tetrahydrofuran (5.0 g) and 2,6-di-tert-butyl-p-cresol (1.1 mg) and dissolved, and then 5A molecular sieves (1.0 g) and p-toluenesulfonic acid monohydrate (11.4 mg, 0.06 mmol) were added, and reacted at 40° C. for 4 hours. N-methylmorpholine (12.1 mg, 0.12 mmol) was added and stirred for a while, and then filtered, and the filtrate was diluted with chloroform (10 g). After repeated washing with 20% saline (10g) of pH 12, the organic layer was dried over anhydrous sodium sulfate and filtered, and distilled under reduced pressure to remove the solvent. The residue was dissolved in ethyl acetate (90g) containing 2,6-di-tert-butyl-p-cresol (18mg), and crystallized by adding hexane (66g), then filtered by suction to obtain crystals. In addition, the crystals obtained were dissolved in ethyl acetate (90g) containing 2,6-di-tert-butyl-p-cresol (18mg), and hexane (66g) was subsequently added to repeat the crystallization operation to remove low molecular weight impurities, and then the compound of formula (45) was obtained after drying under reduced pressure.

[0402] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0403] 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.62(2H, s, -C H2 OH), 5.00(1H, d, -C H2 OCH<), 5.18 (1H, d, -C H2 O-), 5.25 (2H, s, -CH 2 OCO-), 5.97 (1H, s, -C H <), 6.96 to 7.35 (7H, m, arom.H )

[0404] [Chemical formula 62]

[0405]

[0406] (Example 8-2)

[0407] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer was added with a compound of formula (45) (250 mg, 0.0125 mmol) and dichloromethane (3.6 g) and dissolved, and then pyridine (23.7 mg, 0.30 mmol) and p-nitrophenyl chloroformate (40.3 mg, 0.20 mmol) were added, and reacted at 25 ° C for 3 hours. After repeated washing with 20% brine (2.5 g) at pH 12 to remove some impurities, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and crystallized by adding hexane (66 g), and then filtered by suction to obtain crystals. Furthermore, the obtained crystals were dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and then hexane (66 g) was added to crystallize, followed by filtration and drying under reduced pressure, and then the compound of formula (46) was obtained.

[0408] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0409] 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.62(2H, s, -C H2 OH), 5.00(1H, d, -C H2 OCH<), 5.18 (1H, d, -C H2 O-), 5.25 (2H, s, -CH 2 OCO-), 5.97 (1H, s, -C H <), 6.96 to 7.35 (11H, m, arom.H )

[0410] [Chemical formula 63]

[0411]

[0413] (Example 9-1)

[0414] SUNBRIGHT MEH-40T (40g, 2.0mmol), toluene (120g) and 2,6-di-tert-butyl-p-cresol (8mg) manufactured by NOF Corporation were added to a 300mL four-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer, a Dean-Stark tube and a cooling tube, and water was removed by azeotropic removal with toluene. After cooling to 45°C, chloroform (200g) was added, and then cooled to 25°C, and 2-hydroxybenzaldehyde (977mg, 8.0mmol) and triphenylphosphine (2.10g, 8.0mmol) were added. After stirring for a period of time, diisopropyl azodicarboxylate (1.51g, 7.0mmol) was added three times so that the internal temperature did not exceed 35°C. After reacting for 1 hour at 25°C, methanol (224mg, 7.0mmol) was added, and the mixture was stirred for 30 minutes, and then distilled under reduced pressure to remove the solvent. The residue is dissolved in ethyl acetate (320g), and hexane (240g) is added to cause crystallization, followed by suction filtration to obtain crystal. In addition, the crystal obtained is dissolved in ethyl acetate (320g) containing 2,6-di-tert-butyl-p-cresol (64mg), and hexane (160g) is added to repeat the crystallization operation to remove low molecular weight impurities. The crystal is washed with hexane (160g), filtered, and dried under reduced pressure to obtain the compound of formula (47).

[0415] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0416] 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.23 (m, - (OC H2 C H2 ) n -), 9.89(1H, s, -CO H )

[0417] [Chemical formula 64]

[0418]

[0419] (Example 9-2)

[0420] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with the compound of formula (47) (1.0 g, 0.05 mmol), 2,4-bis(hydroxymethyl)phenol (336 mg, 2.0 mmol) synthesized according to the literature (Freeman, JH; JAm. Chem. Soc. 1952, 74, 6257-6260), tetrahydrofuran (5.0 g) and 2,6-di-tert-butyl-p-cresol (1.1 mg) and dissolved, and then 5A molecular sieves (1.0 g) and p-toluenesulfonic acid monohydrate (11.4 mg, 0.06 mmol) were added, and reacted at 40° C. for 4 hours. N-methylmorpholine (12.1 mg, 0.12 mmol) was added and stirred for a while, and then filtered, and the filtrate was diluted with chloroform (10 g). After repeated washing with 20% saline (10g) of pH 12, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (90g) containing 2,6-di-tert-butyl-p-cresol (18mg), and crystallized by adding hexane (66g), then filtered by suction to obtain crystals. In addition, the crystals obtained were dissolved in ethyl acetate (90g) containing 2,6-di-tert-butyl-p-cresol (18mg), and hexane (66g) was subsequently added to repeat the crystallization operation to remove low molecular weight impurities, and then the compound of formula (48) was obtained after drying under reduced pressure.

[0421] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0422] 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.96(1H, d, -C H2 O-), 5.16 (1H, d, -C H2 O-), 5.25 (2H, dd, -C H2 OH), 5.97 (1H, s, -C H <), 6.96 to 7.35 (7H, m, arom.H )

[0423] [Chemical formula 65]

[0424]

[0425] (Example 9-3)

[0426] A 50 mL three-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer was added with a compound of formula (48) (250 mg, 0.0125 mmol) and dichloromethane (3.6 g) and dissolved, and then pyridine (23.7 mg, 0.30 mmol) and p-nitrophenyl chloroformate (40.3 mg, 0.20 mmol) were added, and reacted at 25 ° C for 3 hours. After repeated washing with 20% brine (2.5 g) at pH 12 to remove some impurities, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed by distillation under reduced pressure. The residue was dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and crystallized by adding hexane (66 g), and then filtered by suction to obtain crystals. Furthermore, the obtained crystals were dissolved in ethyl acetate (90 g) containing 2,6-di-tert-butyl-p-cresol (18 mg), and then hexane (66 g) was added to crystallize, followed by filtration and drying under reduced pressure, and then the compound of formula (49) was obtained.

[0427] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0428] 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.96(1H, d, -C H2 O-), 5.16 (1H, d, -C H2 O-), 5.35 (2H, dd, -C H2 OCO-), 5.97 (1H, s, -C H <), 6.96 to 7.35 (11H, m, arom.H )

[0429] [Chemical formula 66]

[0430]

[0431] (Example 10)

[0432] 0.1M sodium phosphate buffer (pH 8.5) is used to prepare the β-alanine buffer of 20mg / mL.In the 50mL three-necked flask equipped with thermometer, nitrogen inlet pipe and agitator, add the compound (70mg of formula (22), 0.0035mmol) and the β-alanine buffer (1.5g) of 20mg / mL and dissolve, and react 6 hours at 25 ℃ subsequently.After dissolving salt (500mg), chloroform (3.0g) is used to extract, and organic layer is dried with anhydrous sodium sulfate and then filtered.Filtrate is diluted with ethyl acetate (45g), and hexane (33g) is added subsequently to cause crystallization, and after filtering, crystal is dried under reduced pressure to obtain the compound of formula (50).

[0433] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0434] 2.28 (3H, s, -C H3 ), 2.48 (2H, t, -C H2 COOH), 3.38(3H,s,-(OCH2CH2) n OC H3 ), 3.39 to 3.45 (2H, m, -C H2 NH-), 3.52 to 4.17 (m, -(OC H2 C H2 ) n -), 4.92(1H, d, -C H2 O-), 5.08 (1H, d, -C H2 O-), 5.15 (2H, dd, -C H2 OCONH-), 5.96 (1H, s, -C H <), 6.79(1H, s, arom.H ), 6.96(2H, d, arom.H ), 7.04(1H, s, arom.H ), 7.50(2H, d, arom.H )

[0435] [Chemical formula 67]

[0436]

[0437] (Example 11)

[0438] 0.1M sodium phosphate buffer (pH 8.5) is used to prepare the β-alanine buffer of 20mg / mL.In the 50mL three-necked flask equipped with thermometer, nitrogen inlet pipe and agitator, add the compound (70mg of formula (25), 0.0035mmol) and the β-alanine buffer (1.5g) of 20mg / mL and dissolve, and react 6 hours at 25 ℃ subsequently.After dissolving salt (500mg), chloroform (3.0g) is used to extract, and organic layer is dried with anhydrous sodium sulfate and then filtered.Filtrate is diluted with ethyl acetate (45g), and hexane (33g) is added subsequently to cause crystallization, and after filtering, crystal is dried under reduced pressure to obtain the compound of formula (51).

[0439] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0440] 2.28 (3H, s, -C H3 ), 2.50(2H, t, -C H2 COOH), 3.38(3H,s,-(OCH2CH2) n OC H3 ), 3.52 to 4.25 (m, - (OC H2 C H2 ) n -), 3.41 to 3.45 (2H, m, -C H2 NH-), 4.91(1H, d, -C H2 O-), 5.08 (1H, d, -C H2 O-), 5.14 (2H, dd, -C H2 OCONH-), 5.94 (1H, s, -C H <), 6.79(1H, s, arom.H ), 7.03 to 7.06 (2H, m, arom.H ), 7.30 to 7.34 (2H, m, arom.H )

[0441] [Chemical formula 68]

[0442]

[0443] (Example 12)

[0444] 0.1M sodium phosphate buffer (pH 8.5) is used to prepare the β-alanine buffer of 20mg / mL.In the 50mL three-necked flask equipped with thermometer, nitrogen inlet pipe and agitator, add the compound (14mg of formula (28), 0.0072mmol) and the β-alanine buffer (3.0g) of 20mg / mL and dissolve, and then react 6 hours at 25 ℃.After dissolving salt (750mg), chloroform (4.5g) is used to extract, and organic layer is dried with anhydrous sodium sulfate and then filtered.Filtrate is diluted with ethyl acetate (45g), and hexane (33g) is added subsequently to cause crystallization, and after filtering, crystal is dried under reduced pressure to obtain the compound of formula (52).

[0445] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0446] 2.28 (3H, s, -C H3 ), 2.47(2H, t, -C H2 COOH), 3.38(3H,s,-(OCH2CH2) n OC H3 ), 3.37 to 3.43 (2H, m, -C H2 NH-), 3.52 to 4.21 (m, -(OC H2 C H2 ) n -), 4.89(1H, d, -C H2 O-), 5.05(1H, d, -C H2 O-), 5.14 (2H, dd, -C H2 OCONH-), 6.22 (1H, s, -C H <), 6.52 to 7.57 (5H, arom.H )

[0447] [Chemical formula 69]

[0448]

[0449] (Comparative Example 2)

[0450] 0.1M sodium phosphate buffer (pH 8.5) is used to prepare the β-alanine buffer of 20mg / mL.In the 50mL three-necked flask equipped with thermometer, nitrogen inlet pipe and agitator, add the compound (143mg of formula (44), 0.0072mmol) and the β-alanine buffer (3.0g) of 20mg / mL and dissolve, and react 6 hours at 25 ℃ subsequently.After dissolving salt (750mg), chloroform (4.5g) is used to extract, and organic layer is dried with anhydrous sodium sulfate and then filtered.Filtrate is diluted with ethyl acetate (45g), and hexane (33g) is added subsequently to cause crystallization, and after filtering, crystal is dried under reduced pressure to obtain the compound of formula (53).

[0451] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0452] 2.47 (2H, t, -C H2 COOH), 3.38(3H,s,-(OCH2CH2) n OC H3 ), 3.37 to 3.43 (2H, m, -C H2 NH-), 3.52 to 4.21 (m, -(OC H2 C H2 ) n -), 4.89(1H, d, -C H2 O-), 5.05(1H, d, -C H2 O-), 5.14 (2H, dd, -C H2 OCONH-), 6.22 (1H, s, -C H <), 6.52 to 7.57 (7H, arom.H)

[0453] [Chemical formula 70]

[0454]

[0455] (Decomposition test)

[0456] Various compounds of formula (50), (51), (52) and (53) (20 mg) were dissolved in sodium phosphate deuterium oxide buffer (0.7 mL) having a pD of 7.4 and then placed in a constant temperature bath at 40°C and NMR measurements were performed at random time points. Figure 1 The amount of β-alanine added at a random time point is shown, assuming that the amount of β-alanine added at 0 hours of standing is 100%. The half-life (t1 / 2) is calculated according to the formula of the approximate formula (wherein ln represents the logarithm with the Napier number as the base, and λ represents the product of the power exponent of the Napier number in the approximate formula of the figure and -1).

[0457] [Mathematical formula 1]

[0458] t 1 / 2 =In(2) / λ

[0459] According to the above calculations, the half-life (t1 / 2) of the compound of formula (50) is 3.6 days, the half-life (t1 / 2) of the compound of formula (51) is 31.5 days, the half-life (t1 / 2) of the compound of formula (52) is 0.55 days, and the half-life (t1 / 2) of the compound of formula (53) is 231 days, which indicates that the compounds of the present invention represented by formulas (50), (51) and (52) have the desired half-life under physiological conditions compared with the compound exemplified in Patent Document 3 represented by formula (53) in the prior art.

[0460] (Example 13)

[0461] RNase A (manufactured by Roche, RNase A from bovine pancreas, Mw=13,700) was modified using the compound of formula (22). 10 mg / mL of RNase A buffer was prepared using 0.1 M borate buffer (pH=8.5), and 10 mg / mL of RNase A buffer (636.3 μL) was mixed with 0.1 M borate buffer (863.7 μL), and then the compound of formula (22) (6.0 mg) was added, and reacted at 20° C. for 20 hours. The reaction solution was filtered, and then HPLC was measured using a cation exchange column under the following conditions. The eluent was monitored by UV and fractionated to obtain a single PEG-RNase A with a purity of 96.1%, which was modified with the compound of formula (22) at one site. Figure 2 HPLC measurements of fractionated mono-PEG-RNase A are shown.

[0462] HPLC device: Thermo Ultimate 3000

[0463] Column: TSKgel SP-5PW (7.5×75mm, 10um; Tosoh Corporation)

[0464] Flow rate: 1mL / min

[0465] Analysis time: 25 minutes (including equilibration)

[0466] Column temperature: 25°C

[0467] Injection volume: 20 μL

[0468] Detector: PDA (measurement wavelength: 280nm)

[0469] Mobile phase A: 5 mM sodium phosphate buffer (pH 8.5)

[0470] Mobile phase B: 5mM sodium phosphate buffer + 0.5mol / L NaCl (pH 8.5)

[0471] Gradient program (A / B): 100 / 0 (-15 minutes) → 100 / 0 (0 minutes) → 33 / 67 (10 minutes)

[0472] (Example 14-1)

[0473] ME-200MS (α-methyl-ω-[(methylsulfonyl)oxy]poly(ethylene oxide) (10 g, 0.5 mmol), 3-methyl-4-hydroxybenzaldehyde (272 mg, 2 mmol), potassium carbonate (0.69 g, 5 mmol) and acetonitrile (50 g) manufactured by NOF Corporation were added to a four-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer, and reacted at 80° C. for 6 hours. After the reaction, the mixture was filtered, concentrated and redissolved in dichloromethane (80 g). Thereafter, a mixture containing 1 wt % potassium carbonate and 10 wt % chlorine was added. (54) is added to the aqueous solution of sodium thiocyanate, and stirred the mixture at 25 ℃ for 10 minutes under a nitrogen atmosphere. After stirring, the mixture was left standstill for 10 minutes, and the organic layer was recovered. Magnesium sulfate was added to the organic layer recovered, and stirred the mixture at 25 ℃ for 10 minutes under a nitrogen atmosphere, and suction filtration was performed subsequently. The filtrate obtained is concentrated, and is dissolved in ethyl acetate subsequently, and hexane is added thereto at 25 ℃ under a nitrogen atmosphere to separate out crystals. The crystal separated out is reclaimed by suction filtration, and is dried under reduced pressure to obtain the compound of formula (54).

[0474] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0475] 2.28 (3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, - (OC H2 C H2 ) n -), 6.93(1H, d, arom.H ), 7.69(2H, d, arom.H ), 9.85(1H, s, - CHO )

[0476] [Chemical formula 71]

[0477]

[0478] (Example 14-2)

[0479] A three-necked flask equipped with a thermometer, a nitrogen inlet tube, a stirrer and a cooling tube was added with a compound of formula (54) (3.0 g, 0.15 mmol), 2,4-bis(hydroxymethyl)-p-cresol (1.0 g, 6.0 mmol), tetrahydrofuran (15.0 g) and 2,6-di-tert-butyl-p-cresol (3.3 mg), and after dissolution, 5A molecular sieves (3.0 g) and p-toluenesulfonic acid monohydrate (34.2 mg, 0.18 mmol) were added, and reacted at 40° C. for 4 hours. N-methylmorpholine (36.4 mg, 0.36 mmol) was added and stirred for a period of time, and then filtered, and the filtrate was diluted with toluene (33.0 g). After repeated washing with 20% brine (30 g) of pH 12, the organic layer was dried over anhydrous sodium sulfate and filtered, and distilled under reduced pressure to remove the solvent. The residue was dissolved in toluene containing 2,6-di-tert-butyl-p-cresol, and hexane was added to induce crystallization, followed by suction filtration and drying under reduced pressure to obtain a compound of formula (55).

[0480] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0481] 2.23(3H, s, -C H3 ), 2.28(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.62(2H, s, -C H2 OH), 4.95(1H, d, -C H2 OCH<), 5.16 (1H, d, -C H2 O-), 5.92 (1H, s, -C H <), 6.8 to 7.3 (5H, arom.H )

[0482] [Chemical formula 72]

[0483]

[0484] (Example 14-3)

[0485] A three-necked flask equipped with a thermometer, a nitrogen inlet tube and a stirrer was added with a compound of formula (55) (500 mg, 0.025 mmol), 2,6-di-tert-butyl-p-cresol (0.5 mg) and toluene (6.0 g) and dissolved, and then triethylamine (38 mg, 0.375 mmol) and p-nitrophenyl chloroformate (50.4 mg, 0.25 mmol) were added, and reacted at 60 ° C for 3 hours. After the reaction, the mixture was diluted with a mixed solvent of ethyl acetate (100 g) and acetonitrile (1.25 g) containing 2,6-di-tert-butyl-p-cresol (20 mg), and crystals were precipitated by adding hexane (50 g), and crystals were obtained by suction filtration. The obtained crystals were dried under reduced pressure to obtain a compound of formula (56).

[0486] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0487] 2.23(3H, s, -C H3 ), 2.31(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.24 (m, - (OC H2 C H2 ) n -), 4.96(1H, d, -C H2 O-), 5.15(1H, d, -C H2 O-), 5.34 (2H, dd, -C H2 OCO-), 5.96 (1H, s, -C H <), 6.8 to 7.4 (5H, arom.H ), 8.23(2H, d, arom.H )

[0488] Number average molecular weight (Mn): 20,223

[0489] [Chemical formula 73]

[0490]

[0491] (Example 15-1)

[0492] The compound represented by formula (57) was obtained in the same manner as in Example 14-1 except that 4-hydroxy-3,5-dimethylbenzaldehyde (300 mg, 2.0 mmol) was used instead of 3-methyl-4-hydroxybenzaldehyde.

[0493] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0494] 2.36(6H,s),3.38(3H,s,-(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, - (OC H2 C H2 ) n -), 7.54(2H, s, arom.H ), 9.88(1H, s, - CHO )

[0495] [Chemical formula 74]

[0496]

[0497] (Example 15-2)

[0498] The compound represented by the formula (58) was obtained in the same manner as in Example 14-2, except that the compound represented by the formula (57) (3.0 g, 0.15 mmol) was used instead of the compound represented by the formula (54).

[0499] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0500] 2.29(3H, s, -C H3 ), 2.36(6H, s), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.68 (2H, s, -C H2 OH), 4.95(1H, d, -C H2 OCH<), 5.16 (1H, d, -C H2 O-), 5.89(1H, s, -C H <), 6.8 to 7.3 (4H, arom.H )

[0501] [Chemical formula 75]

[0502]

[0503] (Example 15-3)

[0504] The compound represented by the formula (59) was obtained in the same manner as in Example 14-3, except that the compound represented by the formula (58) (500 mg, 0.025 mmol) was used instead of the compound represented by the formula (55).

[0505] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0506] 2.29(3H, s, -C H3 ), 2.36(6H, s), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.68 (2H, s, -C H2 O-), 4.95(1H, d, -C H2 OCH<), 5.16 (1H, d, -C H2 O-), 5.89(1H, s, -C H <), 6.8 to 7.3 (4H, arom.H ), 8.23(2H, d, arom.H )

[0507] Number average molecular weight (Mn): 20,072

[0508] [Chemical formula 76]

[0509]

[0510] (Example 16-1)

[0511] The compound represented by the formula (60) was obtained in the same manner as in Example 14-1 except that 2-hydroxybenzaldehyde (244 mg, 2.0 mmol) was used instead of 3-methyl-4-hydroxybenzaldehyde.

[0512] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0513] 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.23 (m, - (OC H2 C H2 ) n -), 6.9 to 7.8 (4H, arom.H ), 10.52(1H, s, -CO H )

[0514] [Chemical formula 77]

[0515]

[0516] (Example 16-2)

[0517] The compound represented by the formula (61) was obtained in the same manner as in Example 14-2, except that the compound represented by the formula (60) (3.0 g, 0.15 mmol) was used instead of the compound represented by the formula (54).

[0518] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0519] 2.29(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.49(1H, d, -C H2 OH), 4.78 (1H, d, -C H2 OH), 4.99(1H, d, -C H2 OCH<), 5.19 (1H, d, -C H2 O-), 6.32 (1H, s, -C H <), 6.8 to 7.7 (6H, arom.H )

[0520] [Chemical formula 78]

[0521]

[0522] (Example 16-3)

[0523] The compound represented by the formula (62) was obtained in the same manner as in Example 14-3, except that the compound represented by the formula (61) (500 mg, 0.025 mg) was used instead of the compound represented by the formula (55).

[0524] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0525] 2.29(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.22(2H, m, -C H2 O-), 4.95(1H, d, -C H2 OCH<), 5.16 (1H, d, -C H2 O-), 6.37 (1H, s, -C H <), 6.8 to 7.3 (8H,arom.H ), 8.23(2H, d, arom.H )

[0526] Number average molecular weight (Mn): 19,942

[0527] [Chemical formula 79]

[0528]

[0529] (Example 17-1)

[0530] The compound represented by the formula (63) was obtained in the same manner as in Example 14-1 except that 2-hydroxy-6-methoxybenzaldehyde (304 mg, 2.0 mmol) was used instead of 3-methyl-4-hydroxybenzaldehyde.

[0531] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0532] 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.23 (m, - (OC H2 C H2 ) n -), 6.6 to 7.8 (3H, arom.H ), 10.53(1H, s, -CO H )

[0533] [Chemical formula 80]

[0534]

[0535] (Example 17-2)

[0536] The compound represented by the formula (64) was obtained in the same manner as in Example 14-2, except that the compound represented by the formula (63) (3.0 g, 0.15 mmol) was used instead of the compound represented by the formula (54).

[0537] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0538] 2.29(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.49(1H, d, -C H2 OH), 4.78 (1H, d, -CH2 OH), 4.90(1H, d, -C H2 OCH<), 5.15 (1H, d, -C H2 O-), 6.8 to 7.7 (5H, arom.H )

[0539] [Chemical formula 81]

[0540]

[0541] (Example 17-3)

[0542] The compound represented by the formula (65) was obtained in the same manner as in Example 14-3, except that the compound represented by the formula (64) (500 mg, 0.025 mmol) was used instead of the compound represented by the formula (55).

[0543] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0544] 2.30(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.22(2H, m, -C H2 O-), 4.95(1H, d, -C H2 OCH<), 5.16 (1H, d, -C H2 O-), 6.6 to 7.1 (5H, arom.H ), 8.23(2H, d, arom.H )

[0545] Number average molecular weight (Mn): 20,915

[0546] [Chemical formula 82]

[0547]

[0548] (Example 18-1)

[0549] The compound represented by the formula (66) was obtained in the same manner as in Example 17-1, except that ME-050MS manufactured by NOF Corporation (2.5 g, 0.5 mmol) was used instead of ME-200MS manufactured by NOF Corporation.

[0550] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0551] 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.23 (m, - (OC H2 C H2 ) n -), 6.6 to 7.8 (3H, arom.H ), 10.53(1H, s, -CO H )

[0552] [Chemical formula 83]

[0553]

[0554] (Example 18-2)

[0555] The compound represented by the formula (67) was obtained in the same manner as in Example 17-2, except that the compound represented by the formula (66) (0.75 g, 0.15 mmol) was used instead of the compound represented by the formula (63).

[0556] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0557] 2.29(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.49(1H, d, -C H2 OH), 4.78 (1H, d, -C H2 OH), 4.90(1H, d, -C H2 OCH<), 5.15 (1H, d, -C H2 O-), 6.8 to 7.7 (5H, arom.H )

[0558] [Chemical formula 84]

[0559]

[0560] (Example 18-3)

[0561] The compound represented by the formula (68) was obtained in the same manner as in Example 17-3, except that the compound represented by the formula (67) (125 mg, 0.025 mmol) was used instead of the compound represented by the formula (64).

[0562] 1H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0563] 2.30(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.22(2H, m, -C H2 O-), 4.95(1H, d, -C H2 OCH<), 5.16 (1H, d, -C H2 O-), 6.6 to 7.1 (5H, arom.H ), 8.23(2H, d, arom.H )

[0564] Number average molecular weight (Mn): 5,400

[0565] [Chemical formula 85]

[0566]

[0567] (Example 19-1)

[0568] The compound represented by the formula (69) was obtained in the same manner as in Example 17-1, except that ME-020MS (1 g, 0.5 mmol) manufactured by NOF Corporation was used instead of ME-200MS manufactured by NOF Corporation.

[0569] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0570] 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.23 (m, - (OC H2 C H2 ) n -), 6.6 to 7.8 (3H, arom.H ), 10.53(1H, s, -CO H )

[0571] [Chemical formula 86]

[0572]

[0573] (Example 19-2)

[0574] The compound represented by the formula (70) was obtained in the same manner as in Example 17-2, except that the compound represented by the formula (69) (300 mg, 0.15 mmol) was used instead of the compound represented by the formula (63).

[0575] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0576] 2.29(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.49(1H, d, -C H2 OH), 4.78 (1H, d, -C H2 OH), 4.90(1H, d, -C H2 OCH<), 5.15 (1H, d, -C H2 O-), 6.8 to 7.7 (5H, arom.H )

[0577] [Chemical formula 87]

[0578]

[0579] (Example 19-3)

[0580] The compound represented by the formula (71) was obtained in the same manner as in Example 17-3, except that the compound represented by the formula (70) (50 mg, 0.025 mmol) was used instead of the compound represented by the formula (64).

[0581] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0582] 2.30(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, -(OCH2CH2) n -), 4.22(2H, m, -C H2 O-), 4.95(1H, d, -C H2 OCH<), 5.16 (1H, d, -C H2 O-), 6.6 to 7.1 (5H, arom.H ), 8.23(2H, d, arom.H )

[0583] Number average molecular weight (Mn): 2,615

[0584] [Chemical formula 88]

[0585]

[0586] (Example 20-1)

[0587] The compound represented by the formula (72) was obtained in the same manner as in Example 14-1 except that 4-hydroxy-2,6-dimethoxybenzaldehyde (364 mg, 2.0 mmol) was used instead of 3-methyl-4-hydroxybenzaldehyde.

[0588] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0589] 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.23 (m, - (OC H2 C H2 ) n -), 6.12(2H, arom.H ), 10.35(1H, s, -CO H )

[0590] [Chemical formula 89]

[0591]

[0592] (Example 20-2)

[0593] The compound represented by the formula (73) was obtained in the same manner as in Example 14-2, except that the compound represented by the formula (72) (3.0 g, 0.15 mmol) was used instead of the compound represented by the formula (54).

[0594] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0595] 2.28 (3H, s, -C H3 ), 2.84(1H, dd, -O H ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, - (OC H2 C H2 ) n -), 4.47(1H, dd, -C H2 OH), 4.75(1H, dd, -C H2OH), 4.98 (1H, d, -C H2 O-), 5.17 (1H, d, -C H2 O-), 6.20 (1H, s, -C H <), 6.57 to 6.55 (2H, m, arom.H ), 6.78(1H, s, arom.H ), 6.97(1H, s, arom.H ), 7.58(2H, d, arom.H )

[0596] [Chemical formula 90]

[0597]

[0598] (Example 20-3)

[0599] The compound represented by the formula (74) was obtained in the same manner as in Example 14-3, except that the compound represented by the formula (73) (500 mg, 0.025 mmol) was used instead of the compound represented by the formula (55).

[0600] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0601] 2.31(3H, s, -C H3 ), 3.38(3H, s, -(OCH2CH2) n OC H3 ), 3.52 to 4.17 (m, - (OC H2 C H2 ) n -), 4.93(1H, d, -C H2 O-), 5.18 (1H, d, -C H2 O-), 5.33 (2H, dd, -C H2 OCO-), 6.26 (1H, s, -C H <), 6.52 to 6.54 (2H, m, arom.H ), 6.87(1H, s, arom.H ), 7.10(1H, s, arom.H ), 7.26 to 7.27 (2H, m, arom.H ), 7.59(1H, d, arom.H ), 8.22(2H, d, arom.H )

[0602] Number average molecular weight (Mn): 20,560

[0603] [Chemical formula 91]

[0604]

[0605] (Example 21)

[0606] 0.1M sodium phosphate buffer (pH 8.5) is used to prepare the β-alanine buffer of 20mg / mL. The compound (74mg, 0.0037mmol) of formula (56) is dissolved in 20mg / mL β-alanine buffer (1.5mL), and then reacted for 6 hours at 25 ℃. After the reaction, the mixture is diluted with 0.1M sodium phosphate buffer (pH 8.5) containing 20wt% sodium chloride, and extracted with chloroform (3g). The organic layer is dried over anhydrous sodium sulfate, and then filtered. The filtrate is diluted with ethyl acetate (45g), and hexane (33g) is added subsequently to cause crystallization, and after filtering, the crystal is dried under reduced pressure to obtain the compound of formula (75).

[0607] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0608] 2.23(3H, s, -C H3 ), 2.28(3H, s, -C H3 ), 2.47(2H, t, -C H2 COOH), 3.38(3H,s,-(OCH2CH2) n OC H3 ), 3.37 to 3.43 (2H, m, -C H2 NH-), 3.52 to 4.21 (m, -(OC H2 C H2 ) n -), 4.89(1H, d, -C H2 O-), 5.05(1H, d, -C H2 O-), 5.14 (2H, dd, -C H2 OCONH-), 5.93 (1H, s, -C H <), 6.8 to 7.7 (5H, arom.H )

[0609] [Chemical formula 92]

[0610]

[0611] (Example 22)

[0612] The compound of formula (76) was obtained in the same manner as in Example 21, except that the compound of formula (59) (74 mg, 0.0037 mmol) was used instead of the compound of formula (56).

[0613] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0614] 2.28 (3H, s, -C H3 ), 2.31(6H, s), 2.52(2H, t, -C H2 COOH), 3.38(3H,s,-(OCH2CH2) n OC H3 ), 3.52 to 4.21 (m, - (OC H2 C H2 ) n -), 3.93 to 3.97 (2H, m, -C H2 NH-), 4.92(1H, d, -C H2 O-), 5.09 (1H, d, -C H2 O-), 5.13 (2H, dd, -C H2 OCONH-), 5.89 (1H, s, -C H <), 6.8 to 7.2 (4H, arom.H )

[0615] [Chemical formula 93]

[0616]

[0617] (Example 23)

[0618] The compound of formula (77) was obtained in the same manner as in Example 21, except that the compound of formula (62) (74 mg, 0.0037 mmol) was used instead of the compound of formula (56).

[0619] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0620] 2.28 (3H, s, -C H3 ), 2.43 (2H, t, -C H2 COOH), 3.38(3H,s,-(OCH2CH2) n OC H3 ), 3.37 to 3.43 (2H, m, -C H2 NH-), 3.52 to 4.21 (m, -(OC H2 C H2 ) n -), 4.92(1H, d, -C H2 O-), 4.97 (1H, d, -C H2 O-), 5.19 (2H, dd, -CH2 OCONH-), 6.32 (1H, s, -C H <), 6.8 to 7.7 (6H, arom.H )

[0621] [Chemical formula 94]

[0622]

[0623] (Example 24)

[0624] The compound of formula (78) was obtained in the same manner as in Example 21, except that the compound of formula (65) (74 mg, 0.0037 mmol) was used instead of the compound of formula (56).

[0625] 1 H-NMR (CDCl3, internal standard TMS); δ (ppm):

[0626] 2.28 (3H, s, -C H3 ), 2.47(2H, t, -C H2 COOH), 3.38(3H,s,-(OCH2CH2) n OC H3 ), 3.52 to 4.21 (m, - (OC H2 C H2 ) n -), 4.89(1H, d, -C H2 O-), 5.03 (2H, dd, -C H2 OCONH-), 5.14 (1H, d, -C H2 O-), 6.53 (1H, s, -C H <), 6.8 to 7.7 (5H, arom.H )

[0627] [Chemical formula 95]

[0628]

[0629] (Decomposability Test 2)

[0630] Various compounds of formula (75), (76), (77) and (78) (20 mg) were dissolved in sodium phosphate deuterium oxide buffer (0.7 mL) with a pD of 7.4 and then placed in a constant temperature bath at 40°C, and NMR measurements were performed at random time points. Figure 3 The amount of β-alanine added at a random time point is shown, assuming that the amount of β-alanine added at 0 hours of standing is 100%.

[0631] According to the calculation formula [Mathematical Formula 1] described in the decomposition test based on the approximate formula of the curve, the half-life (t1 / 2) of the compound of formula (75) is 2.3 days, the half-life (t1 / 2) of the compound of formula (76) is 30.1 days, the half-life (t1 / 2) of the compound of formula (77) is 23.1 days, and the half-life (t1 / 2) of the compound of formula (78) is 1.4 days, which indicates that the compound according to the present invention has a desired half-life under physiological conditions compared with the compound exemplified in Patent Document 3 represented by (53) in the prior art.

[0632] (Comparative Example 3)

[0633] SUNBRIHGT MENP-20T (22.5 mg, 1.13 mmol) manufactured by NOF Corporation and a compound NH2-C6-(Apt-TNFα) (1.8 mg, 141.8 nmol) having a C6 amino linker at the 5' end of the aptamer represented by sequence number 1 were dissolved in 125 μL 100 mM sodium bicarbonate buffer (pH 8.3) and reacted at 40 ° C for 24 hours under a nitrogen atmosphere. WO2019203904A1 reported that the above-mentioned compound NH2-C6-(Apt-TNFα) has TNFα inhibitory activity and has reduced TNFα inhibitory activity after PEGylation. After the reaction, the reaction solution was filtered and then HPLC was measured using a reverse phase column under the following conditions. While monitoring the eluate at 260 nm, the fractionation solution was replaced with PBS by ultrafiltration to obtain PEG(20k)-OCO-NH-C6-(Apt-TNFα), in which the compound of formula (28) having a purity of 98.9% and a GPC peak top molecular weight of 33,101 was bound to Apt-TNFα at a molar ratio of 1:1. Figure 5 In the figure, (A) shows the results of HPLC measurement of fractionated PEG(20k)-OCO-NH-C6-(Apt-TNFα).

[0634] HPLC device: Thermo Ultimate 3000

[0635] Column: Xbridge Oligonucleotide BEH C18 (4.6×50 mm, 2.5 um, manufactured by Waters)

[0636] Flow rate: 1mL / min

[0637] Analysis time: 25 minutes (including equilibration)

[0638] Column temperature: 35°C

[0639] Injection volume: 30μL

[0640] Detector: UV (measurement wavelength: 260nm)

[0641] Mobile phase A: 25 mM hexafluoroisopropanol-15 mM dibutylamine / water

[0642] Mobile phase B: 25 mM hexafluoroisopropanol-15 mM dibutylamine / methanol

[0643] Gradient program (A / B): 70 / 30 (0 min) → 10 / 90 (20 min) → 10 / 90 (30 min)

[0644] (Example 25)

[0645] In the same manner as in Comparative Example 3, except that the compound of formula (28) (22.5 mg, 1.13 mmol) was used instead of SUNBRIGHT MENP-20T manufactured by NOF Corporation, 2MPEG (20k) -OCO-NH-C6- (Apt-TNFα) was obtained, wherein the compound of formula (28) having a purity of 84.7% and a GPC peak top molecular weight of 30,632 was bound to Apt-TNFα at a molar ratio of 1:1. Figure 5 In the figure, (B) shows the results of HPLC measurement of fractionated 2MPEG(20k)-OCO-NH-C6-(Apt-TNFα).

[0646] (Evaluation of TNFα inhibitory activity of PEGylated aptamers)

[0647] 80 μL of viable cells at a concentration of 4 × 10 5 Cells / mL of NF-kB Reporter, luciferase and HEK293 cells (BPS Bioscience Inc.) were added and cultured for 22 hours. Then, 10 μL of 5 μM NH2-C6-(Apt-TNFα) solution, 500 nM PEG(20k)-OCO-NH-C6-(Apt-TNFα) solution or 500 nM 2MPEG(20k)-OCO-NH-C6-(Apt-TNFα) solution was added to each independent well. After addition, 10 μL of 50 ng / mL TNFα solution was added and cultured for 0.5 hours, and then the luciferase activity was measured using the Bio-Glo Luciferase Assay System (Promega).

[0648] The activity was calculated as a relative value with the system not treated with TNFα being set to 0% and the system treated with TNFα being set to 100%.

[0649] The results are expressed as mean ± standard error, and P values ​​were calculated by Student's t-test, with a two-sided P value < 0.05 defined as statistically significant.

[0650] As a result of the evaluation, although the TNFα inhibitory activity of NH2-C6-(Apt-TNFα) and 2MPEG(20k)-OCO-NH-C6-(Apt-TNFα) was confirmed, the TNFα inhibitory activity of PEG(20k)-OCO-NH-C6-(Apt-TNFα) was not confirmed. This indicates that 2MPEG(20k)-OCO-NH-C6-(Apt-TNFα) according to the present invention can continuously release physiological functional substances and can improve pharmacological activity compared to PEG(20k)-OCO-NH-C6-(Apt-TNFα) in conventional technology.

[0651] Figure 6 The results of evaluating the TNFα inhibitory activity using PEG(20k)-OCO-NH-C6-(Apt-TNFα), 2MPEG(20k)-OCO-NH-C6-(Apt-TNF-α), and NH2-C6-(Apt-TNFα) are shown.

[0652] (Comparative Example 4)

[0653] 0.25 mL of 100 mg / mL SUNBRIGHT MENP-20T solution manufactured by NOF Corporation dissolved in acetonitrile was added with 0.25 mL of 29 mg / mL insulin solution dissolved in 0.2 M borate buffer (pH 10.5), and reacted at 25° C. for 3 hours under a nitrogen atmosphere. After the reaction, the solution was replaced with 10 mM ammonium formate buffer (pH 9.0) by ultrafiltration, and then PEG (20k) -OCO-NH-insulin was obtained by anion exchange chromatography under the following conditions. Figure 7 In the figure, (A) shows the results of HPLC analysis of purified PEG(20k)-OCO-NH-insulin.

[0654] HPLC device: Nexera (Shimadzu Corporation)

[0655] Column: Asahipack ES-502N 7C (7.5×100mm, 9um, Showa Denko)

[0656] Flow rate: 1mL / min

[0657] Analysis time: 30 minutes

[0658] Column temperature: 25°C

[0659] Injection volume: 50μL

[0660] Detector: PDA (measurement wavelength: 280nm)

[0661] Mobile phase A: 10 mM ammonium formate buffer (pH 8.5)

[0662] Mobile phase B: 10 mM ammonium formate buffer (pH 8.5) containing 0.25 M ammonium sulfate

[0663] Gradient program (A / B): 100 / 0 (0 minutes) → 67 / 33 (20 minutes) → 0 / 100 (30 minutes)

[0664] (Example 26)

[0665] 2MPEG(20k)-OCO-NH-insulin was obtained in the same manner as in Comparative Example 4, except that the compound of formula (28) was used instead of SUNBRIGHT MENP-20T manufactured by NOF Corporation. Figure 7 In the figure, (B) shows the results of HPLC analysis of purified 2MPEG(20k)-OCO-NH-insulin.

[0666] (Stability Evaluation of PEGylated Insulin)

[0667] 100 μL of 0.5 mg / mL PEG(20k)-OCO-NH-insulin prepared in Comparative Example 4 or 100 μL of 0.5 mg / mL 2MPEG(20k)-OCO-NH-insulin prepared in Example 26 was mixed with 100 μL of 100 mM phosphate buffer (pH 6.0), 100 μL of 100 mM phosphate buffer (pH 7.0), 100 μL of 100 mM ammonium formate buffer (pH 8.0) or 100 μL of 100 mM ammonium formate buffer (pH 9.0), and then allowed to stand at 25° C., and HPLC analysis was performed at random time points.

[0668] For PEG(20k)-OCO-NH-insulin, no decrease over time was observed at any of the measured pH values. On the other hand, for 2MPEG(20k)-OCO-NH-insulin, 2MPEG(20k)-OCO-NH-insulin decreased over time at all measured pH values, and the rate of decrease was particularly high at pH 6.0, confirming a significant increase in insulin. As can be seen from the above, in 2MPEG(20k)-OCO-NH-insulin according to the present invention, the acetal is hydrolyzed over time to release insulin. In addition, the study shows that the hydrolysis of the acetal structure can be reduced under neutral to alkaline conditions.

[0669] exist Figure 8 In the figure, (A) shows the amount of PEG(20k)-OCO-NH-insulin at random time points when the amount of PEG(20k)-OCO-NH-insulin at 0 hours of standing is set to 100%, and Figure 8 In the figure, (B) shows the amount of 2MPEG(20k)-OCO-NH-insulin at random time points when the amount of 2MPEG(20k)-OCO-NH-insulin at 0 hours of standing is set to 100%.

[0670] Industrial Applicability

[0671] The acetal-type releasable polyoxyethylene derivative of the present invention can gradually release biological functional molecules through the hydrolysis of the acetal structure under physiological conditions, thereby improving the pharmacological effects of the biological functional molecules modified with the polyoxyethylene derivative.

[0672] Although the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes or modifications can be made to the invention without departing from the spirit and scope of the invention.

[0673] This application is based on the Japanese patent application filed on April 22, 2022 (Japanese Patent Application No. 2022-070669), the contents of which are incorporated herein by reference.

Claims

1. An acetal-type releasable polyoxyethylene derivative, which is represented by the following formula (1), formula (2), formula (3) or formula (4), and breaks under physiological conditions. [Chemical formula 1] [Chemical formula 2] [Chemical formula 3] [Chemical formula 4] In formula (1), formula (2), formula (3) and formula (4), B 1 represents a hydrogen atom or -C(R 1 )(R 2 )OC(O)E 1 , E 1 represents the leaving group, P 1 represents a polyoxyethylene derivative having a dehydroxylated group, w represents an integer from 1 to 8, R 1 , R 2 , R 3 , R 4 , R 5 and R 11 each independently represents a hydrocarbon group having 1 to 10 carbon atoms or a hydrogen atom, R 6 , R 7 , R 8 , R 9 and R 10 each independently represents an electron-withdrawing substituent, an electron-donating substituent or a hydrogen atom, and m represents 0 or 1.

2. The acetal-type releasable polyoxyethylene derivative according to claim 1, wherein: m represents 0, R 1 and R 2 represents a hydrogen atom, and R 3 , R 4 , R 5 and R 11 Each independently represents a hydrogen atom or a methyl group.

3. A method for producing the acetal-type releasable polyoxyethylene derivative according to claim 1 or 2, the method comprising: A coupling step of coupling the polyoxyethylene derivative with the hydroxybenzaldehyde derivative to obtain a coupling product represented by the following formula (5) or formula (6); Acetalization step, after the coupling step, reacting the coupling product represented by formula (5) or (6) with a hydroxymethyl group at the 2-position and a substituent (-CH=CB) at the 4-position or the 6-position 1 ) m C(R 1 )(R 2 )-OH(B 1 ,m,R 1 and R 2 as described above) under acidic conditions to obtain an acetal structure; as well as A leaving group structure introduction step, after the acetalization step, a leaving group structure (-OC(O)E 1 ) is introduced into the terminal of the substituent at the 4-position or 6-position. [Chemical formula 5] [Chemical formula 6] In formula (5) or formula (6), P 1 ,w,R 6 , R 7 , R 8 , R 9 and R 10 As defined above.

4. The method for producing an acetal-type releasable polyoxyethylene derivative according to claim 3, further comprising between the acetalization step and the leaving group structure introduction step: a deprotection step, deprotecting the amino groups protected by the protecting groups in the coupling products of formula (5) and formula (6); and After the deprotection step, a step is performed to introduce a group capable of reacting with a biological functional molecule into the deprotected amino group.

5. An acetal-type releasable polyoxyethylene conjugate, characterized in that: The acetal-type releasable polyoxyethylene conjugate is represented by the following formula (7), formula (8), formula (9) or formula (10), and is broken under physiological conditions. [Chemical formula 7] [Chemical formula 8] [Chemical formula 9] [Chemical formula 10] In formula (7), formula (8), formula (9) and formula (10), B 2 represents a hydrogen atom or -C(R 1 )(R 2 )OC(O)NHD 1 , D 1 represents a residue obtained by removing an amino group constituting a carbamate bond from an amino group contained in a biofunctional molecule, P 2 It means a polyoxyethylene derivative having a dehydroxylation group, or a combination of a biofunctional molecule and a polyoxyethylene derivative having a dehydroxylation group, w represents an integer from 1 to 8, R 1 , R 2 , R 3 , R 4 , R 5 and R 11 each independently represents a hydrocarbon group having 1 to 10 carbon atoms or a hydrogen atom, R 6 , R 7 , R 8 , R 9 and R 10 each independently represents an electron-withdrawing substituent, an electron-donating substituent or a hydrogen atom, and m represents 0 or 1.

6. A method for producing the acetal-type releasable polyoxyethylene conjugate according to claim 5, the method comprising: a coupling step, reacting the acetal-type releasable polyoxyethylene derivative according to claim 1 or 2 with a biofunctional molecule in a neutral or alkaline buffer, wherein the buffer may contain a water-soluble organic solvent; and The purification step, after the coupling step, is carried out under neutral or alkaline conditions.